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Abstract 
Objectives: Vascular diseases are one of the leading causes of death. Due to minimal 
regenerative capability of the heart, alternative therapies have been sought after with 
engineered biomaterials being extensively investigated in this area. In this study, 
enzymatically degradable heparinised polyethylene glycol (PEG-Hep) hydrogels were 
synthesized and characterised for the binding and controlled release of vascular 
endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), as well as 
their bioactivity and angiogenic potential in vivo. 
 Methodology: VEGF and bFGF were combined into 4% (m/v) PEG-Hep hydrogels. 
The binding and release rates of VEGF and BFGF were analysed via an 
immunosorbent assay. Released growth factor bioactivity was measured using an XTT 
metabolic assay on human saphenous vein endothelial cells and human dermal 
fibroblasts. Neovascularisation was quantified in a subcutaneous rat angiogenesis 
model in which hydrogel growth factor combinations were implanted within porous 
polyurethane discs and analysed after a 4 week period. A novel hybrid hydrogel able 
to degrade proteolytically and hydrolytically was further developed, characterised and 
analysed as above. 
Results: PEG-Hep hydrogels demonstrated substantial growth factor binding ability 
(500-600 ng) and allowed sustained release (10-20 ng/day) for up to 28 days. 
Bioactivity of the growth factors was retained throughout the release period. The 
degradation rate of the hydrogels could be controlled in vivo by varying the ratio of 
monomers capable of forming either hydrolytically or proteolytically degradable 
crosslinks. Qualitative and quantitative analysis demonstrated a pronounced and 
significant angiogenic response in vivo (p<0.05). 
 Conclusion: Heparinised PEG hydrogels show significant promise as controlled 
release vehicles for growth factors and warrant further examination in a myocardial 
infarction model. 
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1. Introduction
Vascular disease is the leading global cause of death and has demonstrated an 
increasing trend in recent years within developing countries (Singelyn and Christman, 
2010). The prevalence of vascular disease has been estimated at between 4.5% and 
29% worldwide, and is highly associated with the male gender (Rao et al., 2007). The 
main cause of vascular disease is atherosclerosis, which is the thickening of the 
arterial wall as a result of invasion and accumulation of white blood cells, smooth 
muscle cells and fatty deposits, creating a fibro-fatty plaque within the blood vessels. 
Vessel blockages are commonly identified in the heart, lower limb and in the brain. 
The constant build-up of atherosclerotic plaque in vessels causes an imbalance in 
oxygen and nutrient supply due to prolonged constant reduction in blood flow resulting 
in ischemia and inflammation (Kurrelmeyer et al., 1998) (Miyahara et al, 2006). 
In cardiovascular cases, atherosclerosis, which limits blood supply to the heart, leads 
to discomfort and angina. Under critical conditions, atherosclerotic plaque develops a 
fibrous outer coating, which weakens and eventually ruptures, leading to blood clot 
formation and arterial rupture, completely diminishing blood supply to the heart and 
compromising myocardial cellular mechanisms. This results in myocardial infarction 
(MI), irreversible cell and tissue damage or death (Figure 1)(Sun and Jia, 2012). MI 
injuries lead to a substantial loss of cardiomyocytes, a cell type with minimal 
regenerative ability. Cardiomyocytes have been determined to have a renewal rate of 
approximately 1-2% per annum in the adult heart (Bergmann et al., 2009) (Senyo et 
al., 2013). Surviving cardiomyocytes therefore need to work harder to maintain the 
sufficient cardiac output in the heart (Perricone and Vander Heide, 2014). Such injuries 
in the heart cause strain and severe cases become pathological (Kurrelmeyer et al., 
1998). This may lead to complications in myocardial perfusion, systolic function and 
severe haemodynamic deterioration (Orlic et al., 2001). 
 Several therapies have been used to re-infuse blocked blood vessels prior to MI injury. 
These therapies include administration of pharmacological adjuvants such as 
antiplatelet therapeutics that help maintain vessel patency, among others (Gerczuk 
and Kloner, 2012). These modern therapies, although useful in some patient cases, 






Figure 1: Schematic Diagram of Myocardial Infarction Progression 
Development of MI occurrence via atherosclerotic build-up in the lining of the coronary artery, 
followed by arterial damage and shortage of oxygen and nutrients. Modified from (Kurrelmeyer 
et al., 1998). 
 
The preferred treatment for patients who have experienced a myocardial infarction is 
coronary angioplasty or thrombolytic stenting (Nallamothu and Bates, 2003). This 
therapy, although reliable, is only useful if a patient is able to have the procedure 
performed within approximately 6 hours after MI occurrence (Epstein, 2007). This is a 
narrow time frame for doctors to use angioplasty and coronary stenting to open 
blocked arteries of heart MI patients. If the patient is unable to get treatment within this 
timeframe, the damage is extensive and such procedures will not be helpful. The 
majority of patients in developing countries are unable to get treatment within such 
limited time due to a lack of resources and therefore require alternative therapies 
(Gibbons et al., 1993).  
The pathological damage and increased stress that occurs after MI often progresses 




1995). Over the past two decades, treatment of chronic heart failure has made 
considerable progress. Pharmacological therapies such as beta-receptor blockers, 
angiotensin-converting enzyme inhibitors, aldosterone antagonists, and 
resynchronization therapy are aimed at reducing progression to heart failure 
(Neubauer, 2007). However, even with the best of modern therapy, stopping the 
progression of heart failure has not been successful, with an annual mortality rate of 
10% (Dayer and Cowie, 2004, Abraham et al., 2002). The only proven cure for heart 
failure is heart transplantation, but this presents a problem as the opportunities for 
patients to receive a donor heart are very low, and transplant patients require frequent 
monitoring, with dependence on immunosuppressant drugs for the rest of their lives 
(Armitage et al., 1990). This suggests that present therapies are inadequate, and there 
is a need for alternative therapies with regenerative ability.  
2. Therapeutic Strategies for Vascular Diseases 
 
Three significant alternative therapies, stem cell delivery, growth factor therapy and 
cardiac hydrogel injection that are being explored in the context of MI are briefly 
delineated below. Then approaches towards optimising a naturally occurring process 
for overcoming ischemia, namely angiogenesis, are discussed with a particular 
emphasis on growth factor delivery in conjunction with hydrogel injection. 
 
2.1. Stem Cell Therapies 
 
The delivery of stem cells through intra-myocardial injection is the subject of intensive 
investigation. Major research focus has been on the adult stem cell populations such 
as mesenchymal stem cells (MSCs), (ADSCs), and bone marrow derived stem cells 
(BMSCs) with many laboratory based studies and clinical trials performed over the last 
15 years (Karantalis and Hare, 2015). The pluripotent embryonic and induced 
pluripotent stem cells though also explored, are impeded in their translation as an 
injectable source due to safety concerns such as potential for teratoma and tumour 
formation though they have proven ability to differentiate towards cardiomyocytes and 
other desirable cell types (Mauritz et al., 2011). The use of the adult stem cell 
populations was originally proposed based on their possible potential to generate new 




that direct regeneration of cardiac tissue through stem cell differentiation most 
probably does not occur (Murry et al., 2004).  
 
It is now understood that the limited therapeutic effect observed most probably results 
from paracrine mechanisms mediated by factors released from stem cells that play 
essential roles in repairing ischemic tissue and promoting angiogenesis (Gnecchi et 
al., 2008). This has most convincingly been demonstrated by the use of conditioned 
media from cultured adult stem cells (Uemura et al., 2006) (Kwak and Mach, 2005). 
The release of biologically active substances in a temporal and spatial manner from 
these cells is probably enhanced by environmental stimuli in the infarct such as 
ischemia, again informed by studies on conditioned media where exposure to hypoxia 
greatly stimulated the therapeutic effect (He et al., 2015). The cytokines and factors 
released influence the microenvironment by acting on a range of different cardiac cell 
types including cardiomyocytes and endothelial cells leading to tissue protection, 
repair, and regeneration (Maltais et al., 2010) (Kamihata et al., 2001). The factors may 
also exert autocrine actions modulating the biology of stem cells, allowing for self-
renewal and proliferation (Takahashi et al., 2006). Stem cells are able to produce a 
wide range of cardio protective and/or angiogenic factors such as vascular endothelial 
factor (VEGF), hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF), 
insulin-like growth factor 1 (IGF-1), epidermal growth factor, keratinocyte growth factor, 
angiopoietin-1 (Ang-1), stromal derived factor-1 (SDF-1), macrophage inflammatory 
protein-1 alpha and erythropoietin (Kinnaird et al., 2004). However, a major limitation 
experienced in stem cell therapy is the poor performance of injected stem cells due to 
their low cell engraftment and survival (Sheng et al., 2012) and this is believed to be 
at least part of the reason for the disappointing results thus far from clinical trials 
(Gyöngyösi et al., 2015) (Fisher et al., 2015). Here hydrogels are being extensively 
explored for their ability to entrap cells at the point of cardiac delivery (Davies et al., 
2016). 
 
As the potentially therapeutically beneficial effects appear to be derived from cell 
secreted bioactive components such as growth factors, this has given further impetus 
towards optimising delivery of the growth factors themselves as this might allow for a 





2.2. Growth Factor Therapies 
 
Direct delivery of proteins has generated much attention as a potentially simpler and 
more defined route for introducing a range of growth factors provided by the paracrine 
effect to the damaged cardiac tissue. The delivery of growth factors via gene therapy 
has also been extensively explored but is beyond the scope of this thesis. In particular, 
growth factors have been investigated due to their potential for stimulating a variety of 
protective mechanisms such as therapeutic angiogenesis (see below), cytoprotection 
of surviving cardiomyocytes and attraction, differentiation and proliferation of 
endogenous stem cells (Urbich et al., 2005) (Gnecchi et al., 2008). The use of VEGF, 
bFGF, HGF and erythropoietin for treatment of MI has progressed to clinical trials, but 
experimental designs have varied considerably over the years, showing significant 
variations in terms of delivery route and dosage of the specific growth factor being 
administered. This variability has certainly contributed to contradictory findings thus 
far (Pascual-Gil et al., 2015).  Undoubtedly, although the use of proteins has been set 
back by aspects such as short half-lives and rapid clearance from the site of delivery 
through blood flow over a period of minutes, in a similar manner to that observed for 
stem cells (Davies et al., 2008). Once again hydrogels are being actively explored as 
a means of overcoming the above issues. 
.  
Although cell and protein based therapies are powerful strategies to therapeutically 
improve ischemic damage, more research is required to advance what has been 
achieved and combat the current disadvantages. It is necessary to improve the 
efficacy of these novel strategies to reach their full potential, and specialised delivery 
mechanisms such as biomaterials have been studied towards achieving these goals.  
3. Hydrogel Injection 
 
Hydrogels have a potential direct application for MI therapy apart from their utility as 
delivery vehicles for stem cells and growth factors. Initial research was directed 
towards the potential ability of injectable hydrogels to mechanically support the 
damaged heart and thus limit increased stress in the wall (Dai et al., 2005) (Singelyn 
et al., 2009). Upon infarction, there is a dilation of the ventricle due to ineffective 




Though compensatory in the short term due to enhanced cardiac output as a result of 
the Frank-Starling mechanism, this dilation and the concomitant wall thinning in the 
infarct region increases wall stress. This increased wall stress can be seen to result in 
part from the Law of Laplace (𝑆𝑡𝑟𝑒𝑠𝑠 = 𝑃𝑟𝑒𝑠𝑠𝑢𝑟𝑒 𝑥   𝑟𝑎𝑑𝑖𝑢𝑠 2 𝑥 𝑊𝑎𝑙𝑙 𝑇ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠⁄ ) and is 
believed to contribute strongly to the relentless progression towards heart failure after 
MI. Injectable hydrogels can reduce wall thinning and thus stress, contributing to 
increased function and preservation of cardiac geometry (Wall et al., 2006) (Kadner et 
al., 2012) (Dobner et al., 2009). Research into the potential of hydrogels to serve as 
mechanical supports is on-going but as observed for so many alternative therapies for 
MI, translation to the clinic is challenging. The reasons for poor translation are 
undoubtedly complex and beyond the scope of this text (Bayés-Genís et al., 2016). In 
addition to hydrogel’s ability to reinforce cardiac tissue as mentioned above, they have 
a range of other capabilities such as the potential to mimic the extracellular matrix 
(ECM) and create a desirable homing environment (De Mel et al., 2008). Over the last 
decade, the number of studies using biomaterials in combination with cell and protein 
therapies has increased exponentially. This is because biomaterial-based delivery 
mechanisms are essential in enhancing outcomes of stem cell and protein therapy in 
vascular diseases (Lam and Wu, 2012). Biomaterials are desirable for their 
biocompatible and biodegradable qualities, with the ability to promote cell migration by 
reproducing aspects of a natural tissue environment, improving cell behaviour by 
producing a 3D environment, increasing viable cell retention to facilitate the paracrine 
effect and enabling prolonged delivery of growth factors by controlling their release 
and protecting them from degradation (Stabenfeldt et al., 2010) (Kim et al., 2008) 
(Cheng and García, 2013).  
 
This review focuses on recent developments in the use of hydrogel biomaterials for 
fuelling therapeutic angiogenesis, with the assistance of angiogenic growth factors. In 
order to achieve optimal results, growth factors may be locally delivered and 
controllably released at the site of injury through altering and reconstructing the 
scaffold chemical composition.  







Angiogenesis is the development of new blood vessels from existing vasculature. It is 
a normal and vital process required for growth, development, and wound healing (Rak 
and Weitz, 2003). The growth of new blood vessels by sprouting and extension from 
pre-existing vasculature is referred to as sprouting angiogenesis (Hellström et al., 
2007) (Risau, 1997). The mechanism of physiological angiogenesis involves a highly 
organized sequence of cellular events, which include vascular initiation, formation, 
maturation and remodelling, controlled and modulated to meet the tissue requirements 
(Staton et al., 2009). Capillary endothelial cells (EC) are an essential component in 
these 4 sequential steps.  
 
The activation of EC for vascular initiation is acquired through the blockage of a cell 
stabilizing signal that occurs through the Angiopoietin-1 (Ang-1) and Tie receptor 
tyrosine kinases. Angiopoietin-2 (Ang-2) plays a critical role in destabilizing vessels by 
promoting pericyte and smooth muscle cells (SMC) detachment (Yancopoulos et al., 
2000). Ang-1 acts as an agonist for Tie-2 properties. The Ang-1 and Tie-2 pathway is 
required for maturation of blood vasculature and EC formation (Ekland et al., 2013). 
This is followed by EC sprouting and migration controlled by VEGF and Notch 
signalling pathways, which dissemble cell adhesion proteins such as vascular 
endothelial cadherin, claudins and occludin with the consequent loosening of inter-
endothelial cell contacts (Vestweber, 2000, Carmeliet, 2000). During migration, ECs 
break down the ECM, proliferate and reorganize into a new vascular sprout driven by 
tip cells down a VEGF gradient. Activation of Notch receptor in the stalk cells (cells 
behind the tip) reduces the ability of these cells to respond to VEGF, but allowing 
controlled proliferation for the extension of capillaries behind the invading tip 
(Prestwich et al., 2006) (Rossant and Howard, 2002). During vessel sprouting, ECM 
is remodelled via degradation mediated by proteinases such as matrix 
metalloproteinases (MMPs) and plasminogen activators with additional control by 
inhibitors of matrix metalloproteinases and plasminogen activator inhibitor thus 
promoting vessel maturation (Chun et al., 2004, GE, 2005).  
 
After new vessel formation, mural cells help stabilize the immature vasculature. The 
recruitment of pericytes expressing platelet-derived growth factor receptor (PDGFR-
β) by EC secreting platelet-derived growth factor-B (PDGF-B) (Jain, 2003) (Van 




role in vessel maturation by assisting interaction of ECs with both mural cells and the 
ECM (Uemura et al., 2002). These mural cells then allow for stable vessel formation 
(Davies et al., 2008). 
 
4.2. Relevance of Therapeutic Angiogenesis 
 
Therapeutic angiogenesis is appealing as a therapy because it aims to augment the 
development of new blood vessels from pre-existing vessels by exogenous 
administration of appropriate growth factors in order to supply blood flow to affected 
ischemic tissue (Mitsos et al., 2012). In the damaged heart it is hypothesised that 
increased angiogenesis will support poorly perfused areas of the surviving 
myocardium and thus limit infarct expansion, attenuating the progression towards 
heart failure (Hao et al., 2007). 
5. Angiogenic Growth Factors  
 
As detailed above, a wide range of growth factors are involved in regulating vessel 
growth.  Apart from those described above, others that have been seen to be pro-
angiogenic include acidic fibroblast growth factor and bFGF, IGF-1, angiogenin, 
transforming growth factor beta (TGF-), tumour necrosis factor alpha, HGF, 
neuregulin, granulocyte-colony stimulating factor, and SDF-1 (Awada et al., 2014) 
(Tang et al., 2009, Dunn et al., 2000) (Jay and Lee, 2013, Kucia et al., 2004). In past 
experiments, although factors such as TNF-, PDGF-BB and EGF directly stimulated 
the formation of new vessels by promoting the sprouting of endothelial cells and their 
growth, these proteins mainly triggered the release of VEGF or the upregulation of 
VEGFR-2 gene (Giraudo et al., 1998, Hoeben et al., 2004). Though VEGF is clearly a 
critical and dominant component of the angiogenic pathway, bFGF has also been 
identified as a potent angiogenic stimulant because it is activated by multiple ligand-
receptor specificities, and triggers a network of signal pathways that promote 
endothelial cell growth, migration, and survival from pre-existing vasculature (Presta 







VEGF is a member of a family of 6 structurally related proteins; VEGF-A to VEGF-E 
and placental growth factor (PIGF) (Mitsos et al., 2012). It exists as a glycosylated 
disulphide-linked homodimer (Figure 2A) and there are 4 major isoforms of VEGF-A 
that range from 121 to 206 peptide residues in humans. These isoforms are VEGF121, 
VEGF165, VEGF189, and VEGF206, where VEGF165 is the dominant isoform (Muller et al., 
1997). Although these isoforms behave identically in solution, they differ in their ability 
to bind to different glycosaminoglycan molecules in the ECM. VEGF165 and VEGF189 
bind the heparin molecule with high affinity, and are sequestered to the cell surface or 
within the ECM bound to proteoglycans, while VEGF121 is freely diffusible and does 
not bind heparin (Shibuya, 2001).   
 
VEGF is produced by a variety of cell types, including keratinocytes, macrophages, 
mast cells, and smooth muscle cells (Nör et al., 1999). It mediates angiogenic effects 
by binding to specific VEGF receptors on the surface of endothelial cells (Muller et al., 
1997). VEGF binds to 3 primary receptors; VEGFR-1, VEGFR-2 and VEGFR-3, and 
various co-receptors. Of the primary receptors, VEGFR-1 and VEGFR-2 are mainly 
associated with angiogenesis (Yancopoulos et al., 2000).  VEGFRs also interact with 
bFGF receptors and with distinct co-receptors such as neuropilins and heparin 
glycosaminoglycans (GAG) important for enzyme, GF, and ECM protein interaction 
for the modulation of biological processes in vitro and in vivo {Ornitz, 2000} (Hicklin 
and Ellis, 2005). VEGFR are classified as type 5 of receptor tyrosine kinases whose 
extracellular domains consist of seven immunoglobulin-like (Ig-like) domains (Stuttfeld 
and Ballmer‐Hofer, 2009). VEGF receptors are activated upon ligand-mediated 
dimerization, which is stabilized by the Ig-like domains, leading to downstream signal 
transduction (Figure 2B). In VEGFR downstream pathway, several signaling proteins 
such as Akt (protein kinase B), focal adhesion kinase (FAK), p38 mitogen-activated 
protein kinase (MAPK), endothelial nitric oxide synthase (eNOS) and phosphoinositide 
3-kinase (PI3K) are activated directly or indirectly via receptor binding (Jiang et al., 
2000) (Eliceiri et al., 1998). These in turn stimulate angiogenesis by inducing vascular 
permeability and vasodilation, EC proliferation, migration, and upregulation of the 
expression of MMP, which initiate the dissolution of the extracellular matrix (Ferrara, 
2002). VEGF was shown to stimulate endothelial production of nitric oxide (NO) and 
prostacyclin (PGI2), two vasodilatory agents that induce permeability of vessels, 




pathways and facilitating angiogenesis. These agents are also known to increase cell-
to-cell interactions by opening junctions between adjacent EC and promote vascular 
smooth muscle cell proliferation necessary for vessel maturation (Hicklin and Ellis, 




Figure 2: Ribbon Representation of VEGF Structure and its Receptor-Binding Domain 
(A) Secondary Structure of VEGF homo-dimer comprised of beta sheets and alpha chains, 
(B) Relationship between VEGF and VEGF receptors initiating angiogenesis via different 





bFGF an 18kDa protein also known as FGF-2 is a member of the heparin binding 
growth factor family (Presta et al., 1994). It was the first pro-angiogenic molecule to 
be identified, and is secreted by human adipocytes and induces the proliferation of 
endothelial cells, smooth muscle cells and chondrocytes (Cross and Claesson-Welsh, 
2001). In normal tissue, bFGF is present in basement membranes, the sub-endothelial 
extracellular matrix of blood vessels, bound to heparin sulphate and stays membrane 




   
The FGF family comprises of 22 members, FGF-1 to FGF-22, which variously bind to 
seven different FGF receptor isoforms, namely FGFR1b; FGFR1c; FGFR2b; FGFR2c; 
FGFR3b; FGFR3c and FGFR4. Among the 22 members of the FGF family, only a few 
have been identified to exert angiogenic properties in vitro and in vivo, and these 
include acidic FGF and bFGF (Johnson et al., 1993). Endothelial cells of different 
origin express FGFR1 and FGFR2, whereas the expression of FGFR3 and FGFR4 
have never been reported (Presta et al., 2005). The bFGF molecule exists as a 
homodimer containing alpha chains and beta sheets (Figure 3A).  
 
bFGF binds to its tyrosine kinase receptor, FGFR-1 inducing dimerization of the 
receptor and thus modulating their effects via downstream signal transduction 
pathways (Yang et al., 2015) (Rak and Weitz, 2003). The binding of bFGF to its 
receptor is stabilised by heparin, facilitating the formation of a complex of two FGF 
molecules and two receptors (Klagsbrun and Baird, 1991). This dimerization leads to 
auto-phosphorylation, which in turn initiates endothelial cell migration, differentiation, 
proliferation and the formation of new blood vessels (Figure 3B)(Cross and Claesson-
Welsh, 2001). 
In the absence of heparin, bFGF binds to its receptor with low affinity and thus affects 
the GF’s angiogenic potential because it is hypothesized that during wound healing of 
normal tissues, the action of heparin degrading enzymes present in the ECM activate 





Figure 3: Ribbon Representation of bFGF Structure and its Receptor-Binding Domain 
(A) Secondary Structure of bFGF homodimer comprised of beta sheets and alpha chains, (B) 
Relationship between bFGF and bFGF receptors initiating angiogenesis via different 
downstream pathways (Cross, 2001). 
 
5.3. Therapeutic Angiogenesis 
 
Initial attempts to achieve therapeutic angiogenesis through delivery of VEGF and 
bFGF were carried out through direct injection of a bolus of single GFs. These early 
clinical and pre-clinical trials had mixed results possibly due in part, to their lack of 
placebos  (Isner et al., 1996) (Schumacher et al., 1998). Certainly concerns raised by 
this initial approach were the possibility of toxic consequences of a large bolus of GF, 
with the potential for edema and hypotension with VEGF (Hariawala et al., 1996) 
(Horowitz et al., 1997). Furthermore it is always desirable to mimic the physiological 
situation where pro-angiogenic factors are released in a sustained manner from a 
localised region such as happens in wound healing (Zisch et al., 2003b). The need for 
localised and sustained delivery has been demonstrated by many including our 
laboratory. Perhaps the most compelling evidence comes from the transgenic mouse 
model where VEGF production could be conditionally switched on and off in the heart 
and liver of adult mice, and vessels lasted for months after VEGF production was 




for longer than 2 weeks for this stability to be achieved (Dor et al., 2002) (Davies et al., 
2008) (Richardson et al., 2001). The localized micro environmental dosage of GF 
delivered was also demonstrated to be critical through the use of myoblasts that 
expressed precise levels of VEGF (von Degenfeld et al., 2006). Here, localized 
delivery between a low and a high threshold was required to generate stable vessels 
without hemangioma formation. 
 
Thus a drive in the field of therapeutic angiogenesis has been the controlled delivery 
of pro-angiogenic factors in a localized manner as might be expected from the ECM. 
Hydrogels are certainly an optimal candidate for this approach because of their 
biological and structural similarity to the ECM. 
6. Hydrogels 
 
Hydrogels have several desirable characteristics that render them suitable as tissue 
regenerative biomaterials, chief amongst which is their ability to provide a highly 
swollen, three-dimensional environment that mimics the ECM and allows the diffusion 
of nutrients, growth factors and metabolites (Zhu, 2010). Indeed, hydrogels are defined 
as three-dimensional polymeric networks swollen by water, the chief constituent of the 
gel system (Zisch et al., 2003b). A further advantage of hydrogels is that they can 
frequently be delivered in an injectable format allowing them to be administered to a 
site in a minimally invasive manner (Nelson et al., 2011, Kofidis et al., 2005). Hydrogel 
precursors ideally should have the potential to gelate under mild conditions due to 
physical changes such as pH, temperature, ionic concentration and chemical reactions 
like Michael addition and Schiff base formation (Lee and Mooney, 2001). It is highly 
important that hydrogels that are utilised for tissue regeneration such as generation of 
vascular tissue be compatible with the site where they are to be administered (Li et al., 
2012). Injectable hydrogels need to satisfy several requirements. They should be 
made of biocompatible materials and biodegrade into biological products (Bensaıd et 
al., 2003, Wang et al., 2010). Their viscosity should be sufficiently low before gelation, 
allowing not only the dispersion of incorporated cells and proteins, but also their 
insudation of solid tissue when injected. Hydrogels must have rapid enough gelation 
rates after in vivo injection, such that they are not dispersed in the circulatory system 




and exhibit a suitable durability to hold cells and proteins and avoid initial burst effects 
(Mooney and Mikos, 1999) (Marler et al., 1998). It is also paramount that hydrogels 
present an adequate percentage of porosity to allow space for cell activity and the 
exchange of nutrients and oxygen (Drury and Mooney, 2003) or allow for cell directed 
invasion of the hydrogel in a manner similar to that of cells in the ECM (Lutolf, 2009). 
There are two major types of hydrogels, natural and synthetic hydrogels, classified 
according to their origin.  
 
6.1. Natural Hydrogels 
 
Natural hydrogels, as implied by their name, are derived from biological polymer-
based materials, such as fibrin, alginate and chitosan. Their inherent biocompatibility 
and ease of production ensured that these types of hydrogels were amongst the first 
to be utilised as tissue regenerative scaffolds (Nelson et al., 2011, Rufaihah and 
Seliktar, 2016). Alginate hydrogels result from ionic interactions between linear, 
unbranched copolymers that contain (1,4)-linked b-D-mannuronic acid, and a-L-
guluronic acid residues. Alginate has been investigated as a delivery vehicle for VEGF 
and PDGF-BB in a rat MI model. In this study, PDGF released more controllably, and 
the relatively sequential delivery generated mature vessels in the infarcted heart (Hao 
et al., 2007). VEGF and bFGF delivered in alginate subcutaneous discs in SCID mice 
elicited a more pronounced angiogenic response. 
 
Chitosan, a linear polysaccharide consisting of N-acetyl-D-glucosamine units is 
derived from chitin via partial deacetylation. Photo-crosslinkable and water-soluble 
chitosan derivatives have been synthesized to make chitosan suitable for hydrogel 
formation. In a previous experiment, bFGF-containing chitosan was photo cross-linked 
on the surface of infarcted rabbit hearts and resulted in functional improvement due to 
increased vascularisation (Fujita et al., 2004). VEGF was also similarly found to be 
pro-angiogenic when delivered from chitosan in a wound-healing model in diabetic 
db/db mice (Obara et al., 2005). 
Another natural hydrogel frequently utilised is fibrin. This hydrogel has been used to 
deliver VEGF and bFGF with potentially promising angiogenic responses in both the 




previously analysed as a cell delivery vehicle, and shown to elicit functional 
improvement and increased angiogenesis as a stand-alone therapy in a rat MI model. 
However, an issue with such direct loading of fibrin, namely burst release and poor 
sustained release was apparent and this is potentially expected for all these types of 
relatively porous natural hydrogels (Tabata, 2000). Certainly this issue is a concern 
with VEGF. The delivery of high doses, through injections or systemic delivery of 
VEGF have previously shown low efficacy, because the majority of the protein is either 
rapidly cleared from the target site or reaches it in insufficient quantities. Furthermore, 
excess amounts of VEGF can cause severe vascular leakage and hypotension (Lee 
et al., 2000).  
 
A significantly utilised approach to increase retention of growth factors in such 
hydrogels, and thereby reduce the burst release effect and sustain delivery has been 
the incorporation of heparin (see below for a detailed description of this proteoglycan) 
(Sakiyama-Elbert, 2014). This proteoglycan has a strong affinity for a wide range of 
growth factors. Lopez et al showed that large doses of bFGF (10 and 100 µg) were 
injected into the myocardium of infarcted pigs after incorporation into alginate in the 
form of microspheres conjugated with heparin. A pronounced angiogenic response 
that stimulated collateral formation blood vessels was observed for both groups, 
resulting in functional improvement (Lopez et al., 1997). A follow up clinical trial with 
the same dosages in coronary artery bypass grafting (CABG) patients observed a 
trend towards better functional recovery in the higher dose arm (Laham et al., 1999). 
Chitosan was also mixed with heparin, which served the dual purpose of forming both 
an injectable format of chitosan (through electrostatic interaction with the negatively 
charged GAG) and control the release of bFGF in subcutaneous mouse and rat 
models to generate a pro-angiogenic response (Fujita et al., 2004). An elegant 
approach to heparinise fibrin was employed by the Hubbell group whereby a heparin 
binding peptide was crosslinked into fibrin with Factor XIII allowing for the 
immobilisation of the heparin and subsequent binding of bFGF (Sakiyama-Elbert and 
Hubbell, 2000) (Ruvinov et al., 2010). However, this system was not directly used for 
stimulating angiogenesis. In a more standard chemical crosslinking approach, bFGF 
from heparin conjugated fibrin was shown to generate neovascularisation in the 





Although natural hydrogels have been determined to possess many advantages useful 
for potential regenerative medicine therapies, they also have limitations in handling 
and engineering, and a potential for immunogenicity {Mano, 2007 #55}. For these 
reasons, a wide range of synthetic hydrogels has been explored in the context of 
therapeutic angiogenesis. 
 
6.2. Synthetic Hydrogels 
 
As indicated above, synthetic hydrogels are desirable due to the control over their 
engineering, allowing the precise introduction of required characteristics. These 
include polymers of poly-acrylic acid (PAA), polyethylene glycol (PEG), its co-polymers 
and poly-vinyl alcohol (PVA).  Some specific advantages that synthetic hydrogels 
possess are photo-polymerization abilities, adjustable chemical and mechanical 
properties, controlled incorporation of bio-functions and control over their transport 
properties (Drury and Mooney, 2003) (Zhu, 2010). Because of their ability to be 
tailored chemically and mechanically, synthetic hydrogels can be sub-divided into 
thermos-sensitive, photosensitive, pH responsive and ion induced hydrogels. When a 
hydrogel’s polymer chains are held together by irreversible covalent chemical 
interactions, the network is relatively strong and stable (Jeon et al., 2011) (Bracher et 
al., 2013). However, the incorporation of reversible molecular interactions allows the 
network to be less robust and is advantageous in being a closer mimic of the 
degradable ECM (Bryant and Anseth, 2003). Degradation of a synthetic hydrogel can 
be designed by introducing either proteolytic or hydrolytic moieties into the polymer 
network. Bioactivity can be designed into the hydrogel by combining growth factors 
and cell specific molecules onto the hydrogel backbone (Seliktar, 2012).  
 
In one approach, a hybrid of natural and synthetic hydrogels was developed where 
fibrin was covalently conjugated with PEG to increase its mechanical durability and 
used to deliver VEGF to infarcted rat hearts. The VEGF loaded injectable hydrogels 
improved function and increased vascularization in the infarcted region (von Degenfeld 
et al., 2006). The polyesters of lactide and glycolide (PLGA) have also shown use in 
delivery of GFs though not in an injectable format. These well tolerated polymers have 
been used in foamed porous hydrogel discs to deliver VEGF and PDGF-BB in both rat 




PDGF-BB containing PLGA microspheres were embedded in the porous VEGF 
bearing scaffolds thus delaying release of PDGF-BB relative to VEGF and the 
staggered release was found to generate stable vessels. 
 
PEG has, of course, not only been used as a cross-linker of fibrin as described above. 
The polymer is of wide interest for regenerative medicine approaches because of its 
inertness, and very tuneable mechanical properties (Oliviero et al., 2012). Our 
laboratory has shown its utility as a biomechanical support in infarcted rat hearts 
(Kadner et al., 2012) (Dobner et al., 2009) and also through its ability to deliver cardio-
protective growth factors that were sterically entrapped as micro-coacervates 
(Johnson et al., 2015).  Thus this polymer is explored in greater detail below. 
 
7. Polyethylene Glycol (PEG) Hydrogel 
 
PEG-based hydrogel is a polysaccharide synthesized and used for its mechanical 
properties. Hydrogels formed from this polymer are listed among the most inert 
synthetic biomaterials, have very low reactivity toward tissue, and are considered to 
possess high biocompatibility {Santin, 2012 #57}. Additionally the versatility of the 
chemistry that can be used to synthesize PEG hydrogel monomers has allowed for 
the design of numerous intelligent gel systems using this molecule (Zieris et al., 2010). 
PEG hydrogels can be polymerised from a linear monomer, or more complex 4-arm 
or 8-arm structures (Figure 4A). A wide range of chemistry is used to form PEG 
hydrogels and their details are beyond the scope of this review. In brief, they include 
free radical polymerisation of PEG acrylates, condensation, click chemistry, chemical 
ligation, enzymatic reaction and Michael-type addition reactions (Figure 4B) (Zhu, 
2010). The latter has shown great promise as an approach towards generating 
intelligent ECM mimic scaffolds and is the chemistry concentrated on by our group. 
The use of the Michael-type addition reaction to polymerise a PEG hydrogel is 
desirable as it can occur at physiological pH without requiring organic solvents and 
does not form damaging free radicals (Lutolf et al., 2001) (Zhu, 2010). In brief, a 
Michael addition involves the formation of a chemical bond between a nucleophile, 
which donates a pair of electrons and is referred to as the Michael donor, and an 




contains one or more carbon-to-carbon double bonds). In the system developed by 
Lutolf and Hubbell, crosslinking is based on a Michael-type addition reaction between 
thiols on the cross-linker molecule and acrylate or vinyl sulfone groups on the termini 
of the PEG monomers (Lutolf et al., 2001). This allows for the crosslinking of a PEG 
hydrogel with peptides containing two cysteine moieties and also the derivitisation of 
the hydrogel with bioactive peptides (Lutolf and Hubbell, 2003). This is beneficial as it 
allows for the creation of synthetic ECM mimics in that the PEG hydrogel is 
enzymatically degradable and can also have cell adhesive peptides attached (Lutolf 
et al., 2001). The latter is critical as PEGs have very low cell adherence and thus the 
combination of this type of hydrogel with bioactive peptides has proven to be a 
necessity for tissue engineering {Censi, 2012 #58}. 
 
 
Figure 4: Structure of Polyethylene Glycol and its Functional Group Derivatives 
Polyethylene glycol constructs in A. Linear for or branched structures (multi-arm form). B The 
end groups of PEG can be converted into the above symmetrical or asymmetrical functional 
groups that allow for different pathways to polymerisation (Zhu, 2010). 
 
Bioactive peptides have been discovered to play a vital role in the function of ECM 
proteins, influencing critical aspects such as cell adhesion and migration {Ruoslahti, 
1996 #59}. The tripeptide RGD, present in all major extracellular matrix (ECM) proteins 
(fibronectin, collagen, laminin), has been the most intensively investigated cell-binding 




The ability to engineer this type of system allows for additions of multiple bioactive 
peptides. Our group has previously shown that combining the laminin derived peptide 
YIGSR with RGD preferentially enhanced migration of endothelial cells on PEG 
hydrogel surfaces relative to smooth muscle cells {Fittkau, 2005 #60}. Thus it is clear 
that this type of Michael addition based PEG hydrogel system can allow introduction 
of components and functions of the ECM in a methodical fashion. 
 
Another aspect mentioned above is the potential to introduce enzymatically 
degradable peptide cross-linkers to allow for cell driven degradation and invasion of 
the hydrogel (Furth et al., 2007)(Figure 5). As the porosity or mesh size of the 
hydrogels formed from branched PEG monomers in the 10-40 kDa, molecular weight 
range is in the 10-30 nm range, cellular movement in 3D within the hydrogels is only 
possible as a consequence of cell mediated proteolysis (Lutolf et al., 2001). In the first 
demonstration of controlled cell invasion, PEG hydrogels were formed from 4-arm 
20kDa vinyl sulfone derivatised PEG monomers (PEG-VS) and cross-linked with 
matrix metalloproteinase (MMP) sensitive peptides. Encapsulated fibroblasts were 
observed to spread and migrate within these hydrogels. The importance of MMP 
activity was demonstrated by either cross-linking hydrogels with MMP-insensitive 
peptides or inhibition of MMP activity, both of which resulted in termination of cellular 
movement. Cellular invasion into hydrogels can therefore be controlled by altering the 
enzyme specificity of the cross-linking peptides (Chun et al., 2004, Bracher et al., 
2013). Fibroblasts and SMC both equally invaded PEG hydrogels cross-linked with a 
sequence that can be cleaved by a range of MMPs, but when an MMP-14 sensitive 
peptide sequence was used, a strong SMC specific invasion was observed (Bracher 
et al., 2013). This once again demonstrates the engineerability of these hydrogels. 
Our laboratory further extended this work to regulate tissue invasion in a subcutaneous 
rodent model assay (Goetsch et al., 2015). Controlling the population of a scaffold and 
its removal by host cells is desirable to allow for an appropriately sustained period of 
release of angiogenic growth factors to generate a stabilized vasculature, or to allow 
for the adequate deposition of matrix proteins by cells when reconstructing structural 
tissues (Bahney et al., 2011). The formation of hydrogels with varying degrees of 
enzymatic degradability through altering the ratios of 2 differentially degradable cross-
linker peptides allowed for control of tissue ingrowth (Goetsch et al., 2015). Importantly, 




stiffness of the hydrogels. Engineered PEG hydrogels containing a combination of 
RGDSP peptide for cell adhesion, and MMP specific cross-linkers were examined as 
cell ingrowth matrices for bone regeneration by the delivery of recombinant human 
bone morphogenetic protein-2 (rhBMP-2) to the sites of defect in rat crania. This 
stimulated fibroblast migration, which remodeled into bony tissue within five weeks. In 
a related study by our group and that of Hubbell, both VEGF165 and an engineered 
VEGF121 that could be covalently coupled into the enzymatically degradable hydrogels 
were found to stimulate in vitro angiogenesis in a chick chorioallantoic membrane 
assay. (Lutolf and Hubbell, 2003), 
               
Figure 5: Polymerization of Enzymatically Degradable PEG-Vinyl Sulfone (VS) Based 
Hydrogels. Michael addition of cysteine containing peptide to the VS end groups (Kasko, 
2013) 
 
In delivery of these types of hydrogel(s) to infarcted hearts, our laboratory showed that 
non-degradable 8-arm PEG vinyl sulfone hydrogels (PEG-VS) coupled by non-
degradable dithiol positively influenced the retardation of left ventricular remodelling 
and dilation (Dobner et al., 2009). However, a possible limitation due to the non-
degradability of the formulation used was an ongoing macrophage-based, foreign 
body response. In a follow up experiment investigating timing of hydrogel delivery after 
MI, MMP degradable hydrogels (8-arm PEG-VS coupled by an MMP degradable 
31 
peptide) showed positive outcomes in the reduction of an inflammatory response to 
the hydrogel, improved scar thickness and function (Kadner et al., 2012).  
As seen from the above, this type of PEG hydrogel system has great engineerability 
and potential as an injectable cardio therapeutic vehicle. These injectable hydrogels 
allow for the construction of engineered ECM mimics by introduction of proteolytic 
degradability and bioactive peptides. However, a key component of the ECM that is 
not present in these hydrogels is the glycosaminoglycans (GAGs). The introduction of 
such a moiety, in particular heparin, would render the PEG gels more ECM-like and 
also greatly expand their angiogenic factor delivery capabilities.  
8. Heparin
Heparin is a glycosaminoglycan that is biosynthesized in the Golgi compartment. Its 
average molecular weight is from 4 to 60kDa but most commercial heparin 
preparations are between 12 and 15kDa (Khorana et al., 2003). The heparin polymeric 
chain is composed of repeating disaccharide unit of D-glucosamine and uronic acid 
linked by 1-4 inter-glycosidic bond (Rabenstein, 2002). Heparin as described above is 
capable of interacting with a wide range of growth factors that contain heparin binding 
motifs. Interactions between heparin and growth factors occur via electrostatic forces 
of attraction between the –N and –O sulphated groups of the heparin (high negative 
charges) and the lysine and arginine groups in the growth factors (high positive 
charges) (Oliviero et al., 2012). The binding of heparin to growth factors has also been 
reported to prevent denaturation and digestion by proteinases {Mano, 2007 #55}. The 
commonly studied angiogenic growth factors VEGF and bFGF express a high affinity 
with heparin, facilitating GF interaction with bFGF’s receptor and promoting receptor 
activation, thus having potential in its use in angiogenesis experiments {Tae, 2007 
#62}. Heparin has been demonstrated by numerous studies to control the release of 
VEGF and bFGF in vivo resulting in increased neovascularisation of implants. 
Our group has recently developed a controlled approach for the functionalization of 
heparin hydroxyl groups with acrylate moieties (van Rensburg et al., 2016). Heparin 




This novel formulation of heparin allows for coupling of the acrylated heparin into the 
PEG-VS hydrogels through thiol containing crosslinkers via a Michael addition reaction.  
 
This chemical modification therefore allows for the relatively facile generation of an 
ECM mimic by covalently coupling heparin into the enzymatically degradable PEG-VS 
hydrogels that are derivatised with cell binding peptides. It is envisaged that this 
potentially more realistic ECM mimic will be a pro-angiogenic vehicle when combined 




It is clear from the above that heparin has shown potential to sustain growth factor 
release and stimulate angiogenesis. Therefore the aims of this study are: 
 
1. To increase the ECM mimicry of the enzymatically degradable PEG hydrogel 
system used by our group through the conjugation of heparin. This system has 
not previously been so modified. 
 
2. Assess the influence of heparin conjugation on growth factor uptake by both 
polymerised hydrogels and hydrogels in a pre-polymerisation state. The former 
will inform on the ability of hydrogels to enhance the paracrine effect of 
encapsulated stem cells and the latter on the potential of these hydrogels as 
injectable growth factor vehicles. 
 
3. Assess the controlled release of the growth factors and determine the 
bioactivity of the released factors. 
 
4. Assess the pro-angiogenic potential of these heparinised hydrogels in an in vivo 







Materials and Methods 
 
10. Preparation of 8-Arm Polyethylene Glycol Vinyl Sulfone (PEG-VS) and PEG 
Acrylate (PEG-AC) Hydrogels 
 
As previously described by our laboratory (Lutolf and Hubbell, 2003), the preparation 
of 20kDa 8-arm PEG-VS and PEG-AC was done by the derivatisation of PEG-OH. In 
brief, PEG-OH was dissolved in dichloromethane (DCM) at a concentration of 1.67% 
w/v,  followed by Sodium hydride (NaH) to deprotonate the solution and excess NaH 
was further quenched by 3.5ml of acetic acid (excess acid until visual colour change 
is seen). For preparation of PEG-VS, vinyl sulfone moieties (Aldrich, Buchs, 
Switzerland) were then added in excess at a 50 to 100-fold molar excess. The solution 
was then added into cold diethyl ether to precipitate PEG. The 20kDa 8-arm PEG-AC 
was synthesized in dry DCM by adding acryloyl chloride to PEG-OH in presence of 
Triethylamine (TEA) in a dry working environment (Sakiyama-Elbert and Hubbell, 
2001) Both precipitated PEG-VS and PEG-AC were vacuum dried (RT, 750 mmHg, 
overnight), purified by dialysis against deionized water (cut off value = 1 kDa, 24 hr) 
and freeze dried. Acrylated heparin (Hep-AC) was synthesized as follows: a heparin 
solution (0.02 g/ml deionized water (DI)) was stirred (30 min, 0 °C, pH = 9.5, 0.5 ml 
0.1 M NaOH), acryloyl chloride (2.5 ml, 20 mole eq of OH groups, 2.5 ml/h) added 
using a syringe pump, and reacted for an additional hour (< 5 °C, pH = 8-9, 10 ml 1-5 
M NaOH).  After vacuum filtration, Hep-AC was isolated by precipitation (ethanol, 0 °C, 
10 x excess volume) and then processed as for the precipitated PEG (van Rensburg 
et al., 2016). All these procedures were performed by the group of Assoc. Prof. Deon 
Bezuidenhout (Cardiovascular Research Unit, UCT). 
Hydrogels were polymerized via a Michael-type conjugate addition between equimolar 
ratios of vinyl sulfone moieties of PEG-VS and thiols of cysteine residues present in 
MMP enzyme recognition peptide cross-linkers. A 1733 Da MMP-1 degradable 
enzyme specific peptide sequence, GCREGPQGIWGQERCG (GenScript USA Inc., 
Piscataway, NJ) was used to form 4% (mass/volume ratio) hydrogels. 1.5% 
(mass/mass) Hep-AC was incorporated into PEG to form part of the polymer. PEG 
was incubated with a 1025 Da RGD adhesion peptide (GCGYGRGDSPG) with a molar 
ratio of 12.5:1 PEG-VS (0.2 mg/120µl iso-PBS) for 20 min at 37°C to allow for cellular 




recognition peptide at respective values indicated in table 1. Hydrogels were brought 
up to total volume using iso-osmotic phosphate buffered saline (Iso-PBS, pH 7.5). Iso-
osmotic phosphate buffer saline (iso-PBS) used for preparation of all hydrogels was 
prepared by mixing 13 ml NaH2PO4.1H2O solution with 87 ml Na2HPO4.12H2O 
solution, to which 100 ml of NaCl was added. The 4% 8-arm PEG hydrogels were 
prepared as in Table 1: 
Table 1: Constituents for 4% PEG Hydrogel Preparation 
Constituents PEG PEG-Hep 1.5% 
10% PEG (10mg/100µl) 20 µl 19.7 µl 
1.5% Hep-Ac (1.5 mg/100mg) - 2 µl 
MMP-1 Peptide  (0.024 mol/L) 16.7 µl 16.7 µl 
Iso-PBS 13.3 µl 11.3 µl 
VEGF/bFGF (1 µg/µl) Relative to Gel Type Relative to Gel Type 
Total 50 µl 50 µl 
 
10.1. Growth Factors 
 
Recombinant human bFGF (154 a.a. catalogue # 100-18b) and recombinant human 
VEGF (catalogue # 100-39) were purchased from Peprotech (New Jersey, USA) and 
reconstituted according to their respective protocols. 
 
10.2. Preparation of GF Soaked PEG Hydrogels 
 
A 4% 8-arm PEG-VS hydrogel stock volume was prepared as described in Table 1, 
excluding the incorporation of GF. Hydrogels (10µl) were carefully pipetted onto sterile 
parafilm layed in a non-tissue culture petri dish and allowed to gel in a tissue culture 
incubator (1 hr, 37°C). Droplets of water were placed around the hydrogel to avoid 
shrinkage. Once set, hydrogels were individually immersed into sterile Eppendorfs 




250 µl 1% Bovine Serum Albumin (BSA-PBS) buffer solution containing either 1 µg 
VEGF, bFGF or both combined and shaken for 24 hrs at 37°C. A wash procedure 
followed where hydrogels were moved to 500 µl 1% BSA-PBS solution and washed 
for 1hr. This was repeated twice to remove excess growth factor washed out after 
gelation. Gels were subsequently immersed in buffer (500 µl iso-PBS, 1% BSA, 0.02% 
sodium azide) at 37°C and eluates were collected and replaced by fresh buffer every 
3 days for 12 days. All washes and eluates removed were stored at -20°C for further 
analysis. 
10.3. Preparation of PEG Hydrogels with Growth Factor added Pre-
Polymerisation 
 
Incorporation of growth factor into hydrogel prior to polymerisation was carried out 
according to table 1 above. Similarly to Section 10, all hydrogel stock solutions were 
prepared beforehand, and differed with growth factors incorporation before gelation 
process. The respective growth factors VEGF and bFGF (1 µl, 1 µg/µl) were added to 
the hydrogel mixture before the addition of MMP-1 enzyme specific peptide. This 
mixture was vortexed, and hydrogels were carefully pipetted onto a parafilm coated 
petri-dish, and allowed to gel in a tissue culture incubator (1 hr, 37°C). Droplets of 
water were placed around the hydrogels and once set, hydrogels were individually 
immersed into a sterile Eppendorf containing 1% BSA-PBS solution and washed (500 
µl, 1 hr). This was repeated twice to remove excess GF unbound during gelation 
process. Gels were subsequently immersed in buffer (500 ul iso-PBS, 1% BSA, 0.02% 
sodium azide) at 37°C and eluates were collected and replaced by fresh buffer every 
3 days for 28 days. All washes and eluates removed were stored at -20°C for further 
analysis. 
10.4. Preparation of hydrolytically/enzymatically degradable PEG hydrogels 
 
A novel formulation of PEG hydrogels was utilised to potentially control tissue invasion 
into PEG-Hep hydrogels and increase growth factor release. PEG hydrogels were 
prepared as explained in section 1, and respective ratios of working concentrations 






Table 2: Constituents for PEG-VS and PEG-AC Hydrogel Degradation Assay 
 Hydrogel Ratio Constituents (PEG-VS : PEG-AC) in µl 










































































VEGF and bFGF were also added to these hybrid hydrogels in the same manner as 
detailed in sec 9.2. 
11. GF Elution Profile Analysis via Enzyme-linked immunosorbent assays 
(ELISA)  
 
The concentration of VEGF and bFGF released from the PEG/PEG-Hep hydrogels 
over time was quantified using enzyme-linked immunosorbent sandwich assay 
(ELISA) experiments. DuoSet® ELISA Development System kits for human VEGF and 
bFGF were obtained from R&D Systems (Minneapolis, USA). ELISA PBS (pH 7.2 – 
7.4) was used to dilute all antibody and 1% BSA diluent reagents. The capture 




in PBS and 100 μl of this was added to each well in a 96-well plate (Nunc, Denmark), 
covered in parafilm and incubated at room temperature overnight. Thereafter the 96-
well plate was washed with 0.05% Tween20 in ELISA PBS (pH = 7.2-7.4, 400 μl, 4 
times) followed by a blocking step with 1% BSA-PBS (300 μl, RT, 1 hr). All eluates 
and wash samples eluate collected over time were diluted to working concentrations 
relevant to growth factor standard curve. Eluate samples were diluted with diluent 
reagent loaded individually and incubated (1:30 dilution, 100 μl/well, 2 hr). The wash 
step was repeated and biotinylated detection antibody was added (1:60 dilution, 100 
μl/well, 1 hr) followed by streptavidin conjugated to horseradish-peroxidase (1:60 
dilution, 100 μl/well, 20 min). A hydrogen peroxide and Tetra-methyl-benzidine 
substrate solution (1:1 working concentration, 100 μl/well, 5 min) was then added, 
monitored for colourimetric development and stopped with 2N H2SO4 (2 M, 50 μl/well), 
monitoring the colourimetric development, followed by the addition of 50 μl of stop 
solution (2 N H2SO4)(Figure 6A).  
Optical density readings were measured using an iMark microplate reader (BioRad, 
California, USA) and taken at 450 nm, with background correction at 570 nm. Growth 
factor standard solutions were made and treated in a similar manner (0.0313–2ng/ml) 
to obtain a standard curve (Figure 6B). The growth factor eluate concentrations (ng/ml) 
were calculated using the curve and cumulative controlled release curves were 
established. The quantity growth factor bound was calculated by subtraction of all 
growth factor contained in washes from the amount loaded. For the soaked hydrogels, 





Figure 6: Quantification of GF Release from Hydrogels using ELISA. (A) Illustration of 
sandwich ELISA process, (B) Standard curve generated from serial dilution of GF for 
calculation of relapsed concentrations. 
12. Cell Culture 
 
Human saphenous vein endothelial cells (HSVEC) and human dermal fibroblasts 
(HdFB) were cultured in MCDB-131 culture media (Sigma-Aldrich M8537, USA), 
constituted with 1% penicillin/streptomycin (Sigma, USA), 1.176 g/L NaHCO3 and 10% 
fetal bovine serum (FBS, Biochrom GmbH, Germany) in a 37⁰C incubator (Hera Cell) 
with 5% CO2. Media was changed every second day.  
 
12.1. Cell Passaging 
 
Cells were grown to 80–90% confluence and then passaged from 75 cm2 (T75) flasks 
(Corning, New York, USA).  Cells were rinsed with sterile Phosphate Buffer Saline 
(PBS) and then lifted using 2 ml Trypsin (Biochrom GmbH, Germany). Trpsynisation 
process was carried out for 3 minutes, followed by inactivation using 2 ml 20% FBS 
MCDB media. The cell volume was pipetted into a 15 ml Falcon centrifuge tube and 
centrifuged at 3000 g for 5 minutes. Supernatant was discarded after centrifugation 
and cell pellet was re-suspended in 1 ml culture medium. Cells in pellet were counted 
by mixing 20μl of the cell suspension with an equal volume of Trypan Blue in a sterile 
Eppendorf tube. 10μl was then loaded onto the haemocytometer (Superior, Germany) 
and a cells were counted using a light microscope (Olympus, Wirsam Scientific, South 
Africa). HSVEC were used between passage 3-5 and HdFB between passage 6-10 
for all experiments. 
12.2. Cell Freezing 
 
Cells were trypsinised and counted as mentioned above (Section 12.1). Freezing 
media containing 5x103 cells was added to cryotube vials (Thermo Scientific, 
Denmark) containing 500 μl of 15% dimethyl sulphoxide (DMSO)(Sigma-Aldrich, 
Missouri, USA) culture medium . A slow freezing method was done, where cryotubes 
were placed on ice immediately after addition of the freezing media and then placed 
in a -80 °C freezer overnight, after which cells were transferred to liquid nitrogen tank 




13. XTT Bioactivity Metabolic Assay 
 
 
To determine the bioactivity of growth factors released from PEG/PEG-Hep hydrogel 
constructs, XTT metabolic assay (Cell Signaling Technology, #9095) was conducted 
on HSVEC and HdFB cells treated with VEGF and BFGF eluted from respective 
hydrogels. The XTT assay is a colorimetric assay for the non-radioactive quantification 
of cellular proliferation and viability, which analyses the number of viable cells from 
their ability to cleave tetrazolium salts added to the culture medium. Cells that are 
metabolically active will reduce the 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-
[(phenyl amino)carbonyl] – 2H– tetrazolium hydroxide (tetrazolium XTT salt) to 
formazan dye (orange in colour) (Huyck et al., 2012). 
A XTT Cell Viability Assay kit was obtained from Cell Signalling Technologies 
(Massachusetts, USA). HSVEC (P3) and HdFB cells (P5) were trypsinised and 5000 
cells were seeded per well in a 96-well plate, with each well containing 100 μl of culture 
medium. After 24 hours HSVEC Cells and HdFB cells were treated with 2% FBS 
MCDB media containing 5 ng/ml VEGF and serum free MCDB media containing 5 
ng/ml bFGF respectively. Cells treated with growth factor-free media were used as a 
control. Cells were incubated at 37°C (5% CO2) and the cell viability was tested using 
XTT assay after 24, 48 and 72 hours. After 48 hours the medium was removed and 
fresh media was added for each respective cell type. The electron coupling reagent, 
phenazine methosulfate (X4751) provided was mixed with the XTT reagent in a 1:50 
ratio, and 50 μl of the solution was then added per well. The plate was incubated 
(37°C, 1 hr) followed by optical density readings at 450nm using an iMark microplate 
reader, with background correction at 655nm. 
14. In vivo Surgical Procedures 
 
All animal experiments involving surgical procedures were approved by the Animal 
Research and Ethics Committee of UCT and complied with the Guide for the Care and 
Use of Laboratory Animals (protocol number: HSFAEC 014/016). Male Wistar rats 
were obtained from the UCT Animal Unit and weighed to establish baseline weights 





14.1. Preparation of Porous Polyurethane Discs 
 
In preparation for subcutaneous assay, porous polyurethane (PU) discs were 
produced as described by Bezuidenhout et al. with a diameter of 5.4 mm and a 
thickness of 1 mm with high porosity (82% porosity, 157 ± 1 µm diameter pores) 
(Bezuidenhout et al., 2002). Discs were sterilized by sonication in a 70% ethanol 
solution for 30 min followed by incubation at RT for 24 hrs. The discs were then air 
dried in the tissue culture laminar flow hood. Various PEG hydrogels groups containing 
the bFGF and/or VEGF were prepared as described above (section 8.2) and RGD 
peptide was included to promote cellular attachment within the hydrogels. 
Unpolymerised PEG hydrogel constituents (25 ul per disc) were mixed and aspirated 
into the PU discs by squeezing the disc consistently (5 times per disc) with a 1 ml 
syringe plunger (Codan Medical Apl., Rodby, DK) to remove trapped air and efficiently 
load the hydrogel. Hydrogel filled PU discs were incubated under sterile tissue culture 
conditions to allow for gelation (37°C, 5% CO2, 2 hr). 
 
14.2. In vivo Subcutaneous Implants 
 
Implants were carried out in male Wistar rats as described by Goetsch et al (Goetsch 
et al., 2015). Animals were anaesthetized (1.5% isoflourane) and shaven, and 1 cm 
longitudinal incisions were made subcutaneously on the dorsal midline and a pocket 
for each disc was aseptically secured via dissection (Figure 7). The discs were 
implanted, within each rat (n = 6) with 6 subcutaneous implants per rat. The different 
hydrogel groups were randomized per rat and the surgeon was blinded to the groups. 
The skin incisions were closed with single 4–0 prolene sutures. After 14 and 28 days 
of implantation, the rats were euthanased by inhalation of halothane and discs were 
explanted with their surrounding capsules, cut into semi-cylindrical sections, and 





Figure 7: Illustration of Subcutaneous Implantation of Hydrogel Filled PU Discs. (A) 
Incision of 1 cm pockets and disc implantation, (B) Discs placed in dorsal line, 6 discs per rat 
  
14.3. Histology  
 
PU discs were explanted and fixed in either paraformaldehyde (Saarchem, 
Kruegersdorp, South Africa), 2.3 mM zinc acetate (Merck KGA, Darmstadt, Germany), 
3.7 mM zinc chloride (Sigma-Aldrich, Steinheim, Germany) in 0.1 M Tris. HCl pH 6.75 
(Sigma-Aldrich, Steinheim, Germany) or zinc fixative (2.8 mM calcium acetate (Merck 
KGA, Darmstadt, Germany) for 24 hr (BD Biosciences, California, USA). Fixing was 
repeated for another 24 hrs. All discs were processed using graded alcohol and 
embedded in paraffin wax. Sectioning of PU samples was performed using a 
Microtome. The 5 µm sections prepared on microscope slides were stained with 
haemotoxylin and eosin (H&E) stained in order to identify cellular invasion. CD31 
staining was also conducted to identify blood vessels in zinc fixed sections. For 
detection of tissue invasion, formaldehyde-fixed sections were incubated in 
Haematoxylin for 5 mins. After a 5 min wash in running tap water, the slides were 
placed in Eosin for 30 seconds, dipped in distilled water, dehydrated through the 
alcohols, before being mounted with Entellan (Merck, Darmstadt, Germany). Vessels 
were detected by incubation with a 1:25 dilution of mouse anti-rat CD31 primary 
antibody (RDI Research Diagnostics Inc., Flanders, NJ, USA) in 1% bovine serum 
albumin (BSA, Jacksons Immunoresearch, West Grove, PA, USA)/PBS for 2 hours at 




tween in PBS prior to using the alkaline phosphatase Biocare Medical kit. Sections 
were incubated with the Rodent body for 30 minutes, followed by two 10 minute 
washes with TBS. The Mouse on Rat alkaline phosphatase polymer was subsequently 
added for 30 min, followed by 2 washes with 0.1 % tween in PBS. Finally, sections 
were incubated with the substrate BCIP/NBT DAKO (DAKO, A/S, Glostrup, Denmark) 
until colour development was complete. After a rinse with running tap water, the 
sections were dehydrated, cleared in 2,2,4 trimethylpentane, and mounted with 
Entellan (Merck, Darmstadt, Germany). Samples were observed and images captured 
with a Nikon Eclipse 90i microscope with Digital Camera DXM-1200C (Nikon 
Corporation, Tokyo, Japan) and micrographs covering an entire cross section of the 
disc were stitched together by automatic scanning (NIS Elements software). The entire 
cross-section was then used for quantitative image analysis. Image analysis for 
vessels was performed by training the Visiopharm Integrated Systems software 
(Visiopharm A/S, Denmark) to automatically detect vessel structures. Tissue invasion 
was done manually using Visiopharm Integrated Systems to delineate areas of 
invasion. In all analyses, the researcher was blinded. 
15. Statistical Analysis 
 
Animal studies were randomized and blinded. Comparison between the groups was 
made by means of 1-way ANOVA (STATISTICA), followed by a two-tailed Student T-
test. Statistical significance was defined at p<0.05. All data are expressed as means 














Results and Discussion 
 
16. VEGF and bFGF Hydrogel Binding Potential and Sustained Release of 
heparinised PEG hydrogels – Modelling the Paracrine Effect 
 
As detailed above, there is considerable evidence that paracrine effects, mediated by 
factors released by adult stem cells, play an essential role in the reparative process 
observed after stem cell injection into infarcted hearts. These cells produce and 
secrete a variety of cytokines, chemokines, and growth factors that may potentially be 
involved in cardiac repair (Gnecchi et al., 2008).  Paracrine factors influence adjacent 
cells and exert their actions through different mechanisms to promote myocardial 
protection, cardiac metabolism, regeneration and neovascularization. It is likely that 
the paracrine factors are released in a temporal manner exerting different effects 
depending on the environment after injury.  
Injectable hydrogels have been used to entrap and localise delivery of stem cells to 
the heart (See Introduction section 3 – Injectable Hydrogels). They can also potentially 
be further used to enhance the therapeutic effect by capturing and sustaining the 
release of paracrine factors.  In this initial study, the capacity of covalently binding 
heparin to a PEG hydrogel to enhance the potential of the PEG hydrogel to bind and 
control the release of growth factors was assessed. If this hydrogel was used to deliver 
cells in an injectable format into the infarcted hearts, the cells would by necessity be 
secreting paracrine factors into a fully polymerised hydrogel. Thus a model was set up 
that mimics this scenario. Hydrogels (covalently conjugated with either 0, 1.5 or 30% 
heparin m/m polymer) were preformed, allowed to fully polymerise (2 hours) and then 
swollen in PBS at 37°C overnight. These fully swollen hydrogels were then incubated 
in GF containing solutions for 24 hrs. After rinsing, the mass of bound GF’s was 





Figure 8: Characterization of Interaction of VEGF and bFGF with PEG and PEG-Hep 
Hydrogels. (A) Total binding of VEGF to PEG, PEG-Hep 1.5%, and PEG-Hep 30%, (B) 
Cumulative release of VEGF from the respective hydrogels over a 12 day period, (C) Binding 
capacity of bFGF to PEG, PEG-Hep 1.5%, and PEG-Hep 30%, (D) Cumulative release of 
bFGF from the respective hydrogels over a 12 day period. (n=4) * Indicates p < 0.001 in 
significance to PEG, $ p < 0.001 in comparison to PEG-Hep 30% and # p < 0.001 in 
comparison to PEG-Hep 1.5% 
 
To evaluate the VEGF binding capacity via the paracrine mimic method, VEGF binding 
potential to PEG, PEG-Hep 1.5% and PEG-Hep 30% was measured in vitro. In Figure 
8A, the VEGF binding results showed 350ng ± 4.2ng bound to PEG (35% bound), 
551ng ± 20.19ng bound to PEG-Hep 1.5%, (55.1% bound) and 750ng ± 20.72ng 
bound to PEG-Hep 30% (75% bound). PEG-Hep 1.5% bound 201ng more VEGF (57% 
increase) in comparison to PEG hydrogel. PEG-Hep 30% bound 400ng more VEGF 
(2-fold increase) compared to PEG. PEG-Hep 30% also bound 199ng more than PEG-
Hep 1.5%. There were therefore substantial and significant increases between PEG 





Figure 8B shows the sustained cumulative release of VEGF from the respective 
hydrogels over a period of 12 days. PEG hydrogel released the least amount of VEGF, 
showing an initial burst release of 2.6ng in the first day, followed by a further 0.37ng 
released per day over the remaining 11 days, with only 6.7ng released in total. PEG-
Hep 1.5% showed a burst release of 36.19ng on day 1, with consistent release over 
the 12 day period, with an average of 6.9ng released per day after the initial burst (all 
per day release rates are given for the period post burst release). 112ng of VEGF was 
released in total. This hydrogel showed a 16-fold increase in release rate compared 
to PEG hydrogel. PEG-Hep 30% showed a burst release of 16.75ng in the first day, 
followed by an average release of 4.05ng per day. 61.58ng of VEGF was released in 
total, with a 10-fold increase in comparison to PEG hydrogel.  
Figure 8C indicates that 235.9ng ± 16.2ng (23.5% bound), 734.61ng ± 26.99ng (73.4% 
bound) and 419.83ng ± 43.2ng (41.9% bound) of bFGF bound to PEG, PEG-Hep 1.5% 
and PEG-Hep 30% respectively. An amount of 499ng more bFGF was bound to PEG-
Hep 1.5%, showing a 2-fold increase over that bound to PEG alone. BFGF bound 
184ng more (78%) in PEG-Hep 30% compared to PEG hydrogel. A 315ng increase 
(75%) in bFGF binding ability was also observed in PEG-Hep 1.5% compared to PEG-
Hep 30%. (p<0.001). It is therefore clear that heparinized hydrogels had a significant 
increase in bFGF binding potential. In this case, the increase in heparin concentration 
to 30% led to a decrease in bFGF binding potential.  
The sustained cumulative release of bFGF from the respective hydrogels is seen in 
Figure 8D. PEG hydrogel showed a burst release of 6.98ng in the first day, followed 
by a rate of 0.74ng per day and a total of 15.24ng released in 12 days. PEG-Hep 1.5% 
showed a burst release of 39.62ng on day 1, with a stable average release of 5.7ng 
per day over the 12 day period, and 103.17ng released in total. PEG-Hep 30% had a 
burst release of 8.85ng of bFGF in the first day, followed by a release rate of 2.54ng 
with 36.76ng of bFGF released in total. The PEG-Hep 1.5% hydrogel resulted in the 
highest bFGF release rate over 12 days. This hydrogel had a 9-fold increase, and 
PEG-Hep 30%, a 2-fold increase compared to PEG hydrogel.  
A further experiment was set up to analyse the binding and release potential of PEG 
and PEG-Hep hydrogels for VEGF and bFGF when the GFs were loaded in 





Figure 9: Characterization of Interaction of VEGF and bFGF loaded in combination, with 
PEG and PEG-Hep Hydrogels. (A) Total binding of VEGF to PEG, PEG-Hep 1.5%, and PEG-
Hep 30%, (B) Cumulative release of VEGF from the respective hydrogels over a 12 day period, 
(C) Binding capacity of bFGF to PEG, PEG-Hep 1.5%, and PEG-Hep 30%, (D) Cumulative 
release of bFGF from the respective hydrogels over a 12 day period. (n=4). * Indicates p < 
0.001 in significance to PEG, $ p < 0.001 in comparison to PEG-Hep 30% and # p < 0.001 in 
comparison to PEG-Hep 1.5%. 
 
The binding of VEGF and bFGF to the different hydrogels when loaded in combination 
(Figure 9A and C) indicated a similar trend when loaded singly (Figure 8A and C). 
Figure 9A showed 143.38ng ± 19.03ng (14.3% bound), 378.14 ± 22.91ng (37.8% 
bound), and 601.45 ± 35.5ng (60.1% bound) of VEGF was bound to PEG, PEG-Hep 
1.5% and PEG-Hep 30% respectively. A 1.6-fold increase was seen in PEG-Hep 1.5% 
compared to PEG hydrogel (p<0.001), with 235ng more VEGF bound to heparin 
molecules. A 3.2-fold increase was seen in PEG-Hep 30% compared to PEG hydrogel, 
with 458ng VEGF bound to the heparin. (p<0.001). Here again, heparin concentration 
significantly increased the binding of VEGF. 
A sustained release of VEGF was observed from the hydrogels. PEG released 
21.21ng of VEGF in 12 days, with a burst release of 12.2ng in the first day and a daily 




a burst release of 52.65ng on day 1, followed by an average rate of 8.09ng per day 
and 141.03ng released in total. PEG-Hep 30% released 33.2ng in a burst on the first 
day, followed by a release of 4.9ng per day, with a total of 87.59ng released in 12 days. 
The presence of heparin in PEG hydrogel significantly increased the rate of growth 
factors release, showing a 7-fold increase with PEG-Hep 1.5%, and a 4-fold increase 
with PEG-Hep 30%.  
The binding potential of bFGF was also analysed, and figure 9C showed 101.65ng ± 
24.5ng (10.1% bound), 376.84 ± 39.14ng (37.6% bound), and 235 ± 34.34ng (23.5% 
bound) was bound to PEG, PEG-Hep 1.5% and PEG-Hep 30% respectively. PEG-
Hep 1.5% had 275ng more of bFGF bound (2.7-fold increase), and this was bound to 
the heparin incorporated in the hydrogel. PEG-Hep 30% bound 134ng more bFGF (2-
fold increase) due to heparin compared PEG respectively. The presence of heparin in 
these hydrogels increases their binding potential, showing a clear significant increase 
in PEG-Hep 1.5% compared to PEG (p<0.001), and significant increase in bound 
BFGF on PEG-Hep 1.5% compared to PEG-Hep 30% (p<0.001).  
In figure 9D, sustained bFGF release was analysed and PEG released 30.91ng in 12 
days. This was observed as the highest amount of growth factor released from PEG, 
in comparison with all other PEG hydrogel release profiles assayed. In this hydrogel, 
18.31ng was released due to burst effect in the first day, followed by an average of 
1.09ng released per day. PEG-Hep 1.5% hydrogel showed a burst release of 37.35ng 
in the first day, followed by a steady release of 5.27ng of bFGF per day with a total of 
95.84ng released in 12 days. PEG-Hep 30% showed a burst release of 13.67ng in the 
first day, followed by 3.06ng released per day, and a total of 50.39ng of bFGF released 
in 12days. PEG-Hep 1.5% had a 3-fold increase in bFGF release rate, and PEG-Hep 
30% showed a 60% increase in bFGF release rate compared to PEG hydrogel. 
The observation of the amounts of bFGF bound and released was substantially lower 
compared to VEGF amounts, but still significant in the model described above. Though 
it has been demonstrated by our laboratory in collaboration with the inventors, Hubbell 
group, of this proteolytically degradable PEG hydrogel system that the VS moieties on 
the PEG are able to covalently bind growth factors through exposed sulfhydryls on 
their cysteine molecules (Zisch et al., 2003a), it was expected that in the scenario 
described above that all VS would have been reacted with the sulfhydryls contained 
in the crosslinking peptide sequence during polymerisation. This does not appear to 




during polymerisation is at a sufficient level to allow for the capture of some of the 
growth factors. This capture is most probably enhanced by the 24hr incubation period 
in the growth factor solution. However as shown above and discussed below, heparin 
substantially increased growth factor capture and greatly elevated the release rates of 
the two growth factors examined here.  
VEGF and bFGF showed similar trends in binding and sustainable release for both the 
single and combined loading hydrogel profiles. Table 3 shows the amount of growth 
factor bound to heparin molecules in each growth factor binding analysis. VEGF bound 
in similar amounts to PEG-Hep 1.5% in both the single growth factor experiment, and 
when loaded in combination with bFGF. A similar trend was seen with PEG-Hep 30%. 
The binding of bFGF to PEG-Hep 1.5% and PEG-Hep 30% between single and 
combination growth factor profiles was also increased by heparin, but the amount of 
bFGF was less in the combination study, particularly for the PEG-Hep 1.5% (Table 3). 
An anomaly is, that though PEG-hep 30% hydrogels bound the highest amount of 
VEGF as might be expected, this was not observed for bFGF. This unexpected result 
was observed in both the single and combination studies and thus is reproducible. It 
is not clear why the increased heparin concentration did not bind additional bFGF 
molecules and this observation requires further investigation. It seems unlikely that the 
affinity of heparin for the two growth factors might play a role here as bFGF has been 
shown with surface plasmon resonance analysis to have an approximately 8 fold 
higher affinity for heparin than VEGF (Ashikari-Hada et al., 2004).  
Table 3: Amount of Growth Factor Bound to the Heparin Moiety  
 
 Single  Combination  
 VEGF bFGF VEGF bFGF 
PEG-Hep 
1.5% 
201ng 499ng 235ng 275ng 
PEG-Hep 30% 400ng 184ng 458ng 135ng 
 
 The release rates for the heparinised gels is, in almost all cases, substantially 
elevated above that of PEG hydrogels. In this area, the behaviour of the two different 




had a lower cumulative release rate in comparison to PEG-Hep 1.5%. Although it 
might have been predicted, at least for VEGF, that PEG-Hep 30% would have a higher 
release rate due to more VEGF bound to the hydrogel, a probable reason for the 
observed low release rate is that high levels of heparin significantly increase the 
hydrogel’s overall avidity for GF, thus reducing the ability of the VEGF to escape the 
hydrogel. The especially pronounced effect of increased heparin concentration on 
bFGF release rates might, in this instance, reflect the higher affinity of heparin for this 
GF. This phenomenon has also been observed by Pike et al for VEGF and bFGF 
release from heparinised hyaluronic hydrogels (Pike et al., 2006). Thus it is clearly 
important to titrate the heparin content in hydrogels for optimal binding and release 
rates. In the studies above, it is clear that PEG-Hep 1.5% is the optimal concentration 
of the two heparin gels tested here and later work in this project focused on the PEG-
Hep 1.5% hydrogels. As stated above, the ultimate aim of this portion of the project 
was to determine the suitability of these hydrogels as an injectable hydrogel for cardiac 
delivery of MSC to infarcted hearts. The data presented above resulted in the choice 
of PEG-Hep 1.5% for such a study carried out by our laboratory and collaborators at 
the University of Pavia, Italy. The hydrogel formulation did significantly enhance the 
capture and therapeutic efficacy of injected MSC in a rat infarction model (the 
associated manuscript is presently undergoing review). 
 
17. Characterisation of VEGF / bFGF loaded in an injectable appropriate 
manner 
 
Though the above experiments demonstrated the suitability of heparinised PEG 
hydrogels to serve as a scaffold for capturing stem cell secreted paracrine factors after 
hydrogel polymerisation, this type of hydrogel also has the potential to deliver growth 
factors in a controlled release manner after cardiac injection. In this type of scenario, 
growth factors would need to be contained in the pre-polymerised solution prior to 
injection and subsequent in vivo polymerisation.  Thus further experiments were 
carried out, whereby hydrogels were formed in that exact manner with VEGF and 
bFGF contained in the pre-gel solution. As PEG-Hep 1.5% had been shown to behave 
optimally of the two heparin concentrations used above, it was assessed for its 
potential to bind and control the release of the growth factors over a further extended 








Figure 10: Characterization of Interaction of VEGF and bFGF mixed in PEG and PEG-
Hep 1.5% Hydrogels. (A) Total binding of VEGF to PEG and PEG-Hep 1.5% (B) Cumulative 
release of VEGF from the respective hydrogels over a 28 day period, (C) Total binding of 
bFGF to PEG and PEG-Hep 1.5% (D) Cumulative release of bFGF from the respective 
hydrogels over a 28 day period. (n=4) * = p<0.001 in (A) and (C). 
 
VEGF binding capacity was assayed after polymerisation of the hydrogel solutions 
with growth factor present. After washing, as for the previous binding experiments, 
435.79ng ± 44.58ng VEGF was bound to PEG (43.5% bound) and 842.17ng ± 14.10ng 
bound to PEG-Hep 1.5% (84.2% bound) (Figure 10A). A substantial increase in VEGF 
binding was observed in PEG-Hep 1.5% compared to PEG alone, where PEG-Hep 
1.5% bound a 406ng more VEGF (2-fold increase) in comparison to PEG hydrogel 
(p<0.001). Figure 10B shows the sustained release of VEGF from the respective 
hydrogels over a 28-day period. PEG hydrogel released a small amount of VEGF, 
showing an initial burst release of 3.8ng in the first day, followed by a further 0.73ng 




Hep 1.5% showed a burst release of 24.25ng on day 1, with consistent release over 
the 28-day period, showing an average of 5ng released per day. 160ng of VEGF was 
released in total. This hydrogel showed a 7-fold increase in release rate compared to 
PEG hydrogel. PEG-Hep 1.5% released approximately 33% of VEGF bound to the 
heparin in the hydrogel over the 28-day period. Figure 10C indicates that 501.34ng ± 
30.09ng (50.1% bound), and 745.19ng ± 36.7ng (74.5% bound) of bFGF bound to 
PEG and PEG-Hep 1.5% respectively. An amount of 234.85ng of bFGF was bound to 
the heparin molecules in the PEG-Hep 1.5% hydrogel, showing a 47% increase in 
binding potential, compared to PEG alone (p<0.001).  
Figure 10D shows sustained release of bFGF from PEG and PEG-Hep 1.5% over 28 
days. PEG hydrogel released 5.2ng in the first day, followed by a further 0.34ng 
released per day over 27 days, with only 14.47ng released in total. PEG-Hep 1.5% 
showed a burst release of 14.82ng on day 1, with consistent release over the 28 day 
period, showing an average of 3ng released per day. 97.81ng of bFGF was released 
in total. This hydrogel also showed a 9-fold increase in bFGF release rate compared 
to PEG hydrogel. PEG-Hep 1.5% released 34% of bFGF bound to the heparin in the 
hydrogel over 28 days. Thus, in this injectable growth factor delivery model, 
heparinisation of the PEG again significantly increased bound growth factor and also 
substantially elevated growth factor release levels. Interestingly, the amount of growth 
factor bound to the non-heparinised PEG did not differ as much as might have been 
predicted as a consequence of the raised levels of vinyl sulfone moieties temporarily 
available during polymerisation. If the binding for the single growth factors to a pre-
polymerised PEG hydrogel (Figure 10) are compared to those in Figure 8, 25% more 
VEGF and 2-fold more bFGF was bound when growth factors were pre-mixed. This 
suggests that both the reaction rate of the thiolated peptide cross-linker as being much 
higher due to its hugely higher concentration relative to the growth factors (2000 and 
4000 fold for bFGF and VEGF respectively), and the reduced time available for 
crosslinking in the pre-mix scenario (1 hr vs. 24 hr for the paracrine model), greatly 
limited binding of the growth factors to the VS moieties during polymerisation.  
 
*Soak method: Polymerised Hydrogel + Growth factor mixture = Growth factor 
captured in Hydrogel 
*Mix method: Pre-polymerised hydrogel + GF = growth factor incorporated Hydrogel 
Polymerisation 
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18. Bioactivity of Hydrogel Released VEGF and BFGF
As the growth factors were released over an extended period of time (28 days) at 37°C, 
the bioactivity of the growth factor fraction released at the 28 day time point was 
determined. This would allow for the potential of the heparinised PEG hydrogels to 
retain and control the release of growth factors in a manner that was suitable for 
generating neovascularisation.  VEGF and bFGF released from PEG-Hep 1.5% 
hydrogels at 28 days were assayed for their influence on the proliferation of human 
saphenous vein endothelial cells (HSVEC) and human dermal fibroblasts (HdFB) 
respectively. First, a dose response assay was set up to identify the optimal growth 
factor concentration to test on the different cell lines. Bioactivity of 28 day eluted growth 
factors was then analysed. 
Figure 11: Dose Response Tested VEGF and bFGF Released from PEG-Hydrogel 
Promote Cell Proliferation. The XTT based absorbance was measured for VEGF stimulated 
HSVEC (A and C) and bFGF stimulated HdFB cells, (B and D). A dosage response was 
established for VEGF (A) and bFGF (B). The response at 72 hr for fresh and 28 day eluted 
VEGF (C) and bFGF (D) was then determined (n=3) * =p<0.01 relative to no VEGF control. 
As observed in dose response assays shown in figure 11, increases in VEGF and 
bFGF concentrations led, as expected, to increases in HSVEC and HdFB proliferation 




respectively. The 5ng/ml concentration was chosen to further analyse growth factor 
bioactivity eluted from the hydrogels, because this was the lowest concentration that 
showed a pronounced effect for proliferation of both cell types, particularly after 72 hr 
culture. In Figure 11C, a similar trend was seen in increased XTT based absorbance 
for HSVEC treated with fresh versus eluted VEGF. Fresh VEGF showed an increase 
in absorbance readings from 0.28 in untreated cells to 0.37 units (33% increased 
metabolic activity), and eluted VEGF increased to 0.35 units (26% increase in 
metabolic activity) after treatment for 72 hr (p<0.01). No significant difference was 
noted between fresh VEGF and eluted VEGF, indicating maintained bioactivity. The 
bioactivity profile in Figure 11D showed that eluted bFGF increased absorbance from 
0.3 to 0.402 units (34% increase in metabolic activity) in comparison to untreated cells 
and fresh bFGF showed an increase from 0.3 to 0.44 units (47% increase in metabolic 
activity). Both fresh and eluted bFGF significantly increased in cellular metabolic 
activity (p<0.01), and although differences were observed between fresh and eluted 
bFGF, there was no significant difference, thus indicating maintained bioactivity.  Thus 
both VEGF and bFGF retained full bioactivity over the 28-day elution period, 
suggesting that these hydrogels could elicit an angiogenic response when implanted 
subcutaneously.  The observation that the growth factors are stable over this period is 
supported by other work carried out by our laboratory, where VEGF contained in an 
osmotic pump implanted in a rat was shown to be fully active after 42 days (Davies et 
al., 2008). 
The above work is the first, to our knowledge, describing the capture and controlled 
release from an injectable synthetic ECM in the form of a heparinised PEG hydrogel 
cross-linked with proteolytically degradable peptides. However, due to heparin’s 
affinity for a broad range of growth factors, heparin has been used widely to covalently 
derivatise other natural and synthetic hydrogel polymers. The discussion here will 
focus on the more injectable formats of heparin derivatised biomaterials though 
heparin has been used to enhance the growth factors’ binding and release potential 
of a wide variety of pre-formed polymeric scaffolds such as polyurethane (Davies et 
al., 2011) collagen (Wissink et al., 2000) and poly(L-lactide-co-glycolic acid) (Jeon et 
al., 2006). 
 
In past experiments, after activating the carboxylic acids on heparin with N-




hydrochloride (EDC)(Yang et al., 2010b), the activated heparin was reacted with 
amines on fibrinogen. This heparinised fibrin was mixed with natural fibrin before 
polymerisation with thrombin. The derivatised natural hydrogel was found to release 
bFGF at a steady rate of about 3% per day at a rate roughly similar to that assayed in 
the above controlled release studies. This natural hydrogel has promise as injectable 
formulation due to the FDA approval of unmodified fibrinogen. Another naturally 
occurring polymer that has been used extensively by the Peattie group to form 
heparinised GF release hydrogels is hyaluronic acid (Peattie et al., 2004) (Pike et al., 
2006) (Elia et al., 2010). Here, thiolated heparin was reacted with thiolated hyaluronic 
acid via a crosslinking PEG-diacrylate. The hydrogels were shown to release both 
bFGF and VEGF in the presence of exogenous heparin but, as also observed in our 
study, release rates were very much curtailed with increasing amounts of heparin (Pike 
et al., 2006). Indeed, for both growth factors, it was found necessary to add thiolated 
gelatin to increase release rates. The exact reason for this was unclear, but it was 
speculated that the shorter chain lengths of the gelatin molecules compared to those 
of the hyaluronic acid chains, might have reduced steric hindrance to the eluting 
growth factors. It is noteworthy that the potential crosslinking of the growth factors to 
the PEG diacrylate via their cysteines was postulated for these hyaluronic acid 
hydrogels (AC and VS both form covalent links with sulhydryls through Michael 
addition reactions, the former forms a hydrolytically degradable bond and the latter a 
stable covalent link). Both these hydrogel types have promise due to their innate 
biocompatibility but potentially lack the engineerability achievable with the synthetic 
ECM PEG analog analysed in the preceding sections. Additionally, they are less well 
chemically defined as a result of their purification from biological sources (Lutolf et al., 
2001). 
Several studies have examined the potential of hydrogels formed via the use of 
modified heparin and PEG chains. In one instance, heparin was thiolated and then 
cross-linked with a PEG diacrylate (Choi et al., 2008). The release of human growth 
hormone was compared between pure PEG hydrogels and the heparin cross-linked 
hydrogels. Unlike our hydrogels with their defined proteolytically degradable peptide 
crosslinkers, these would rely solely on hydrolytic degradability. Heparin was found to 
sustain the release of growth hormone from the PEG hydrogels. Interestingly, though 
a high percentage of polymers were used to form these hydrogels (10-15% vs the 4% 




observed. This is in contrast with that observed for our hydrogels and that detailed 
above for the hydrogels from the Peattie group (Pike et al., 2006) (Peattie et al., 2004). 
The reason for this difference is not clear but it may reflect the particular protein used, 
namely human growth hormone. In a different approach, thiol binding groups were 
added to heparin, namely maleimide, and the maleimide heparin was then reacted 
with thiolated PEG (Nie et al., 2007). These hydrogels might be expected to be 
minimally degradable due the stable link formed between the maleimide and the thiols. 
Here again, higher heparin concentrations resulted in slower release rates of bFGF 
but also an elegant study was carried out where the polymer percentage was varied. 
This showed that even if the ratio of heparin was kept low, a higher concentration of 
the two polymers caused a decrease in release. Again it was speculated that this might 
be due to covalent links between the bFGF and the maleimide of the heparin. 
Perhaps the most similar system to ours is that described in a series of studies from 
the Werner group (Tsurkan et al., 2010) (Zieris et al., 2010). These hydrogels are star 
PEG based (4 arm relative to our 8 arm PEGs) and the PEGs are reacted via terminal 
amines with EDC/NHS treated heparin. In certain instances, an MMP degradable 
peptide was pre-coupled to the star PEG prior to reaction with the modified heparin 
(Prokoph et al., 2012). The cell binding peptide RGD was also coupled to the heparin 
prior to hydrogel polymerisation (Zieris et al., 2010) (Prokoph et al., 2012) (RGD was 
also used in our hydrogel system for all in vivo studies below). Although this system 
allows for the same engineerability as our system, the chemistry is less specific and it 
might be expected that proteins incubated with the polymers whilst gelation was 
occurring could be extensively cross-linked to the heparin via free amines. Amines are 
present in much higher amounts in proteins relative to thiols (Wu et al., 2015).  It may 
be for this reason that release studies were carried out for this EDC/NHS based 
system only in a manner analogous to the paracrine model described above, where 
hydrogels are pre-formed for 24hr and then soaked in growth factor solution. A variety 
of growth factors such as bFGF, VEGF and SDF-1 have been assessed for control of 
their release. These hydrogels are characterised by a relatively large burst release in 
the first few days followed by a fairly flat release rate. This may result from covalent 
coupling of the protein to the hydrogel. These hydrogels were also able to bind both 
bFGF and VEGF together in a similar fashion to our hydrogels. Thus it is apparent that 
the heparinised hydrogels analysed in this project behave similarly to those reported 




advantages to those discussed above. Therefore their ability to stimulate angiogenesis 
in a subcutaneous rat model was examined below. 
 
19. Neovascularisation of proteolytically degradable hydrogels releasing bFGF 
and VEGF 
 
VEGF and bFGF containing PEG-Hep 1.5% hydrogels were prepared singly and in 
combination and then polymerised within porous polyurethane (PU) discs (Figure 12). 
These types of PU discs have been utilised extensively by our laboratory as scaffolds 
for localising neovascularisation in a rat subcutaneous angiogenesis model (Davies et 
al., 2008) (Bezuidenhout et al., 2002). The discs allow for clear delineation of the target 
area for potential neovascularisation after explantation. Their substantial porosity 
allows for easy and uninhibited ingress of tissue. 
 
 
Figure 12: Scanning Electron Microscopic (SEM) Pictures of Porous 
Polyurethane (PU) Discs. PU discs with a diameter of 6 mm and a thickness of 1mm 
(50x magnification). (B): Discs show well-defined open porosity of 82%, a pore size of 






Figure 13: CD31 Immunohistology of PU Discs Explanted at 28 Days. A. PEG-
Hep 1.5%; B PEG-Hep 1.5% VEGF; C PEG-Hep 1.5% bFGF D PEG-Hep 1.5% 
bFGF/VEGF (Size bar D 500 µm) E. High magnification: Arrowhead indicating 





Figure 14: Capsule Vessel Density Quantified in PEG-Hep 1.5% Hydrogels Mixed with 
VEGF or bFGF, and IHC Stain of Explanted PU Discs with CD31. (n=6) 
In figure 13 above, explanted PU discs were stained with CD31 to identify vessel 
ingrowth induced by the sustainable release of VEGF and BFGF into the hydrogel, 
showing their potential to induce an angiogenic effect. As seen in figure 13 above, 
hydrogel filled PU discs showed very little evidence of vessel ingrowth after 
explantation at 28 days. In our laboratory, the analysis of vessel ingrowth into the 
scaffold has been the standard process because of its well-defined area for 
quantification of neovascularisation of the hydrogel (Davies et al., 2011). This measure 
of vascularization was not possible for this particular experiment, and an attempt was 
made to analyse the influence of released GF on neovascularization in the surrounding 
capsule. Capsule sizes showed substantial variability within the different groups, and 
no significant difference in area of vascularisation was observed. Though VEGF and 
bFGF were released at apparently reasonable rates from PEG-Hep 1.5%, this did not 
induce a significant effect on the capsule vessel density (Figure 14). It is not clear 
whether the varying encapsulation of the discs influenced vessel density due to 
differing distances for growth factors to travel (considerable variability within each 
group was observed for capsule size, capsule sizes such as in Fig 13A and 13D were 
observed in each group), or it could simply represent an inadequate growth factor 
release rate. As an important aim of these types of cell dependent degradable 
hydrogels is to generate new vessels in the region previously occupied by the hydrogel, 
a new strategy was required where the hydrogels would degrade more rapidly but 
retain the aspect of cell dependent invasion. For these reasons, a novel formulation of 
the PEG hydrogels that might allow for sufficient ingrowth into the PU scaffold and an 
increased release of growth factor was developed. Thus, a hybrid scaffold was formed 
with different combinations of 8-arm PEG Acrylate (PEG-AC) and PEG-VS molecules 
cross-linked by the MMP degradable peptides. The PEG-AC molecule forms 
hydrolytically degradable crosslinks with thiol cross-linkers whilst the PEG-VS forms 
very stable crosslinks (Dobner et al., 2009) (van Rensburg et al., 2016). This novel 
approach therefore allows for both bulk hydrolytic breakdown and cell directed 
enzymatic degradation to occur simultaneously. 
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20. Control of Tissue Invasion into Hybrid Hydrolytically and Enzymatically
Degradable PEG Hydrogel
To analyse which ratios of PEG-AC and PEG-VS would be ideal for both desired 
degradation rate for tissue invasion, an experiment was set up to analyse the in vivo 
degradation rates of hybrid hydrogels. It was desirable to determine what ratio of AC 
and VS molecules would allow for complete ingrowth into the porous PU discs over a 
28-day period. This is a period used by our group that allows for the detection of stable
vessel formation, and also roughly corresponds with 4-5 weeks time period in which
remodelling of cardiac tissue is complete in a rat heart, the ultimate target for these
hydrogels. In this experiment, hydrogels polymerised from ratios of PEG-VS (%): PEG-
AC (%) of 100:0; 75:25; 50:50; 25:75 and 0:100. Heparin loaded at 1.5% m/m of total
polymer was used exclusively in this and further experiments because this heparin
loading had shown the highest growth factors binding and release potential. These
various formulations were polymerized within the porous PU scaffolds and implanted
subcutaneously for 14 and 28 days. H&E staining allowed for clear visualisation of
newly formed tissue and the presence of non-degraded hydrogel (Figure 15).
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Figure 15: H&E staining of PU discs containing heparinised PEG hybrid hydrogels 
explanted at 14 (A-F) and 28 days (G-K).  PEG-VS %: PEG-AC %:  100:0 (A;G); 75:25 
(B;H) 50:50 (C;I) 25:75 (D;J) 0:100 (E;K). size bar 500 µm (E; K). (F) Higher magnification 
of blocked region in (B). Arrowhead indicating intact hydrogel; arrow indicating tissue. Size 
bar 100 µm.
As is clear from the micrographs, the percentage acrylate had a marked influence on 
the invasion of tissue into hydrogels that were formulated with the same percentage 
of total polymer. Thus, hydrogels containing 50% to 100% of PEG-VS hydrogel 
showed very little to no tissue ingrowth at 14 days, and hydrogels with lower PEG-VS 
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incorporation (25% and 0%) showed essentially complete tissue invasion. After 28 
days implantation, the 50% VS group now showed complete tissue ingrowth with 
occasional traces of hydrogel remaining. PEG-VS 25% and PEG-VS 0% hydrogels 
were, of course, fully ingrown at 28 days as was already seen at 14 days. The 75 and 
100 % VS groups showed a small increase in invasion, the invasion for the 100% VS 
group was also expected from the first in vivo angiogenesis study described above 
(See Section 19). 
Quantitative image analysis of the cross-sections confirmed the initial observations. 
After 14 days, hydrogels containing 100%, 75% and 50% PEG-VS had tissue ingrowth 
of 2%, 12% and 11% respectively, showing minimal cellular invasion, while hydrogels 
containing 25% and 0% PEG-VS showed tissue ingrowth of 97% and 100% 
respectively. After 28 days, hydrogels containing 100% and 75% PEG-VS had 29% 
and 30% tissue invasion, whereas hydrogels containing 50%, 25% and 0% PEG-VS 
showed 87%, 100% and 100% tissue ingrowth (Figure 19). These findings show that 
controlled invasion of tissue into the hydrogel can be obtained by titrating hydrolytic 
groups with groups that can only be broken apart by enzymatic activity. This, to our 
knowledge, novel approach complements previous work by our group where PEG-VS 
hydrogels were cross-linked with differing combinations of a readily degradable MMP 
cleavage sequence, with one with low degradation potential (Goetsch et al., 2015). 
The use of differentially degradable peptides allowed for a finer control over invasion 
than observed for the hydrolytic/enzymatic approach described above. However, it is 
possible that the use of different ratios to those used might allow for further control. 
Thus, hydrogels that are expected to be mechanically similar could allow for different 
ingrowth rates. This is useful as ingrowth control is usually obtained by varying the 
stiffness of the gel, which, by necessity, varies other parameters (Goetsch et al., 2015). 
Though similar stiffness is expected based on previous work in the laboratory, this has 
yet to be confirmed by rheological analysis. 
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Figure 16: Hybrid Hydrogel In vivo Degradation. Image analysis of tissue ingrowth into the 
porous PU discs as a percentage of ingrowth area available. (n=4) 
 The results assessed above led the selection of the 50% hybrid hydrogel construct as 
the most desirable in controlling for degradation. This is because it appeared to persist 
for almost 28 days, with traces of hydrogel still visible suggesting that growth factors 
should be delivered over the entire period This hydrogel was therefore assessed for 
its growth factors binding ability and sustainable release over 28 days. 
21. Characterization Heparinized Hybrid Hydrogel on VEGF and bFGF binding
as an injectable scaffold
The heparinised 50% hybrid hydrogel pre-polymerised with VEGF and bFGF, was 
assayed for its ability to bind and release said GFs over 28 days. 
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Figure 17: Characterization of Interaction of VEGF and bFGF mixed in 50% PEG-
VS/PEG-AC Hybrid Hydrogels. (A) PEG-Hep Hybrid Hydrogel interaction with VEGF alone 
and in combination with bFGF (B) Cumulative release of VEGF from the respective hydrogels 
over a 28 day period, (C) PEG-Hep Hybrid Hydrogel interaction with bFGF alone and in 
combination with VEGF (D) Cumulative release of bFGF from the respective hydrogels over 
a 28 day period. (n=4) 
VEGF binding potential to PEG-Hep 1.5% hybrid hydrogel was measured in vitro. In 
Figure 17A, 1950ng ± 3.43ng (97.5% bound) and 1945ng ± 10.1ng (97% bound) of 
VEGF bound to hybrid hydrogel as a single growth factor, and in combination with 
bFGF respectively.  
Figure 17B shows the sustained cumulative release of VEGF from the respective 
hybrid hydrogels over a period of 28 days. VEGF, singly bound to the hybrid hydrogel, 
showed an initial burst release of 53.99ng in the first day, followed by a further 9.28ng 
released per day over the remaining 27 days, with 304.69ng released in total. The 
VEGF bound in combination with another growth factor showed a burst release of 
61.05ng on day 1, followed by an average release of 8.75ng released per day over 27 
days. 297.42ng of VEGF was released in total. As seen in figure 17B, there was a 
consistency observed in the release rate over the 28 days, and VEGF released alone 
or in combination with bFGF showed a similar trend in cumulative release. 
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In Figure 17C, 1860ng ± 14 (93% bound) and 1849ng ± 3.61ng (92% bound) of bFGF 
bound to hybrid hydrogel as a single growth factor, and in combination with VEGF 
respectively. Figure 17D showed the sustained cumulative release of bFGF from the 
respective hybrid hydrogels over 28 days. bFGF bound to the hybrid hydrogel alone 
showed an initial burst release of 55.87ng on the first day, followed by a further 
12.78ng released per day over the remaining 27 days, with 400.93ng released in total. 
The bFGF bound in combination with VEGF showed a burst release of 56.47ng on 
day 1, followed by an average release of 10.96ng released per day over 27 days. 
352.57ng of VEGF was released in total.  
Double the amount of hydrogel (20ul) was assessed in this experiment, with a 
corresponding increase in growth factor (2ug) loaded in comparison to the 10 µl 
hydrogels loaded with 1 µg growth factors used for the previously described release 
assays. This was, to show more clearly the true amounts expected to bind and release 
in an in vivo model, as this is the quantity of hydrogel and growth factor that was, and 
would be used, in the angiogenesis assays. According to figure 17, it is possible that 
hybrid hydrogel constructs allowed for an increase in GF binding compared to pure 
PEG-VS hydrogels (VEGF binding: hybrid 97%; PEG-VS 82%. bFGF binding: hybrid 
92%; PEG-VS 75%). A potential reason for this could be the incorporation of AC 
moieties into the hydrogel. But as both AC and VS bind to sulfhydryls via a Michael 
addition with similar kinetics, it is not expected that PEG-AC would have a marked 
influence on growth factor binding to what has already been observed with PEG-VS. 
However, in future experiments, this potential influence should be assayed (van 
Rensburg et al., 2016). 
Hybrid hydrogels showed similar VEGF release rates compared to PEG-Hep 1.5% 
(100% VS) hydrogels in both the paracrine model (Figure 8 and 9) and mixed GF 
experiments (Figure 10). The bFGF release rate however showed a 3-fold increase in 
hybrid hydrogels compared to that observed in the pure VS PEG-Hep 1.5% hydrogels. 
It is somewhat slightly surprising that bFGF showed such a substantial increase in 
release rate whilst VEGF did not. As noted above, bFGF is known to have a higher 
binding affinity for heparin and is therefore expected to release more slowly. A slower 
release was indeed observed for the 100% VS hydrogels (Figure 10). To potentially 
gain a clearer understanding of this possible discrepancy, as mentioned above, further 
experiments with non-heparinised hybrid hydrogels should be performed. 
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As the 50% hybrid hydrogel released both growth factors at similar or even elevated 
levels than the pure PEG-VS hydrogel previously analysed in the subcutaneous 
angiogenesis model, and also showed suitable degradation, this formulation was 
assessed for its pro-angiogenic potential. 
22. Hybrid Hydrogel Angiogenesis Potential
The potential of the growth factors bound to the 50% hybrid hydrogel to induce 
angiogenesis was again assayed in the rat subcutaneous angiogenesis model. PU 
discs were filled with growth factors containing 50% hybrid hydrogels and implanted 
for 28 days. In this study, an empty PU disc group was included as an additional control. 
The full cross-sections (Figure 18) show that, as predicted, there was substantial 
ingrowth into the hydrogel filled discs with vessel invasion throughout for all groups. 
This was optimal for quantification because it allowed for the measurement of vessel 
density in a well-defined area, as previously used in our laboratory. 
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Figure 18: CD31 immunohistology of PU dics containing heparinised hybrid 
PEG hydrogel explanted after 28 days (complete cross sections). (A) Empty control 
disc (B) PEG-Hep hybrid (C) PEG-Hep hybrid VEGF (D) PEG-Hep hybrid bFGF (E) 
PEG-Hep hybrid bFGF/VEGF. Size bar 500 µm 
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Blinded image analysis of area occupied by vessels in the various groups showed that 
the incorporation of VEGF, bFGF or their combination, significantly increased the 
neovascularisation within the hydrogels (Figure 19). Empty PU discs and PEG-Hep 
hybrid control showed 3.2% and 3.02% in average vessel percentage area, in 
comparison to the hydrogel area. Growth factor containing hydrogels showed 
significant increases to 4.3%, 4.8% and 4.7% percentage area for VEGF, bFGF and 
their combination respectively relative to both the empty disc and PEG-Hep controls 
(p < 0.05)(Davies et al., 2011). It is clear that the incorporation of GF to the heparinised 
hybrid hydrogel induces substantial increases in vessel ingrowth of 44, 59 and 55% 
as observed for VEGF, bFGF and their combination relative to PEG-Hep. This 
demonstrates that the PEG hybrid hydrogels are able to control the release of these 
two important growth factors in a manner that can achieve a robust angiogenic 
response. The extent of the response is similar to other studies assaying angiogenesis 
stimulation by release of these two factors from scaffolds and other hydrogels (Pike et 
al., 2006) (Davies et al., 2011) (Elia et al., 2010). It had been expected that the 
combination of VEGF and bFGF would show a synergistic effect (Pike et al., 2006) but 
this was not observed. However, other researchers have also failed to discern a 
synergism in combinations of bFGF and VEGF (Zieris et al., 2010) (Cao et al., 2003). 
Figure 19: Hybrid in vivo Angiogenesis Assay. CD31 treated PU discs filled with GF 
containing hybrid hydrogel after 4-week period. Discs analysed for vessel ingrowth were 
analysed qualitatively and quantitatively. Percentage area of ingrowth was quantified and 
represented graphically. (n=6,). * = p<0.05 in comparison to PEG-Hep Control and # = p < 
0.05 in comparison to Empty PU. 
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The above findings indicate that the heparinised hybrid hydrogels allow hydrogel 
degradation to be controlled, and that the resultant controlled release of VEGF and 
bFGF is sufficient to generate a substantial increase in vessel ingrowth. This suggests 
that this type of hydrogel would be a useful candidate for injection into damaged 
cardiac tissue after infarction, and may allow for regain of function and limitation of 
pathological remodelling. 
23. Conclusion
The above work details a characterisation of the potential of heparinised PEG based 
hydrogels for either potentiation of the stem cell paracrine effect or as injectable GF 
release vehicles. 
In the first study, the utility of these hydrogels was explored in a manner that simulated 
the situation, if these hydrogels were used as an injectable vehicle for stem cell 
delivery to an infarcted heart. Fully polymerised heparinised hydrogels were found to 
be able entrap and release significant levels of VEGF and bFGF. This indicates their 
promise as stem cell delivery vehicles with the ability to potentiate the paracrine effect. 
Though non-heparinised PEG hydrogels entrapped substantially less growth factors 
and had very low release rates, it was still somewhat unexpected that they were able 
to entrap growth factors after polymerisation. It is assumed this entrapment must 
derive from interaction of growth factors with unreacted VS moieties, this finding 
requires further investigation. 
In the main body of the research, the capability of the heparinised hydrogels as 
injectable growth factors delivery vehicles was investigated. Here again, significant 
increases in entrapment and release rates were observed relative to non-heparinised 
PEG hydrogels. As the first therapeutic target would be increased neovascularisation, 
their efficacy was assessed in a rat subcutaneous angiogenesis model. Surprisingly, 
considering the level of VEGF and bFGF release observed in vitro, no enhancement 
of angiogenesis was observed. It was speculated that this might have resulted from 
the minimal tissue invasion observed into the hydrogels utilised that require cell based 
enzymatic degradation.  
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Thus, a novel approach towards possibly increasing invasion rates and also release 
rates was explored. Heparinised PEG hydrogels were formed that had variable 
proportions of PEG molecules that can break down hydrolytically, namely PEG-AC. 
These hydrogels were indeed found to be able to control tissue invasion in a 
subcutaneous model. Hydrogels that contained higher proportions of the hydrolytic 
component were fully invaded within 14 days whilst an intermediate version had a 
degradation period of 28 days. As expected, those with higher ratios of the 
enzymatically degradable component persisted to at least 28 days. Certainly, further 
investigations are warranted into the fine-tuning of this system with other ratios of the 
two monomers. 
The intermediate hybrid hydrogel with the desirable degradation profile was then 
assayed for VEGF and bFGF entrapment and release. Though the hydrogel was 
equivalent to the pure enzymatic hydrogels in the initial studies in entrapment as 
expected, similarly it did not have a higher release rate. This was unexpected, as the 
loss of the hydrolytic component should have reduced steric hindrance to growth 
factors escape. This finding requires further assessment of the influence of the PEG-
AC moieties and a thorough biomechanical analysis of the hydrogels over the release 
period. 
Nevertheless, as the intermediate hybrid hydrogel had the required tissue invasion 
rate, a subcutaneous angiogenesis assay was performed. Here a pronounced and 
significant increase was observed for both VEGF, bFGF and their combinations. Thus, 
the novel hybrid heparinised PEG hydrogels show promise as another means of 
controlling growth factors release from an injectable hydrogel. 
Because the threshold at which protein will no longer bind is not known. There would 
be some value to knowing the threshold and a scientific approach focused on testing 
effects of various concentrations of protein on hydrogel binding would be analysed. 
This was not explored due to time constraints and the very substantial expense 
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